Archive for the ‘Genetic Testing’ Category

Global Genetic testing services Market presents an in-depth review and technical research, with useful facts and figures, of the current and future state of the Genetic testing services market worldwide. Genetic testing services market provides information on emerging market opportunities and business factors, developments and evolving technologies that will fuel these growth trends. The report provides a comprehensive overview including Comparison of Definitions, Range, Use, Production and CAGR (percent), Form Segmentation, Share, Revenue Status and Outlook, Capacity, Demand, Market Drivers, Production Status, and Outlook and Opportunities, Export, Import, Growth Rate for Emerging Markets / Countries.

Get Sample Copy of this Report https://www.factmr.com/connectus/sample?flag=S&rep_id=4744

Our industry professionals are working reluctantly to understand, assemble and timely deliver assessment on impact of COVID-19 disaster on many corporations and their clients to help them in taking excellent business decisions. We acknowledge everyone who is doing their part in this financial and healthcare crisis.

The market research study on Genetic testing services was collected through comprehensive primary research through interviews, surveys, and findings of experienced analysts and secondary research. The study also provides a complete qualitative and quantitative assessment by analyzing data obtained from industry analysts and market participants from Genetic testing services around key points in the value chain of the industry.

The Regional Analysis of This Report Covers the Following Major Companies

Useful findings of this research are-

-Study of historical data.

-Analysis of existing scenarios in every domestic and national sector.

-Study of patterns, accessible knowledge and data figures.

-Use of validated project methods for the next five years.

Statistical analysis, figures and prime data included in the report contains-

-Market size (current and projected for the last few years)

-Market share analysis as per different companies)

-Market forecast)

-Demand)

-Price analysis)

-Market contributions (Size, Share according to geographical boundaries)

The report benefits Market Investigators, companies, Vendors, Buyers, Suppliers, Individual professionals and Competitive organizations

A Customization of this Report is Available upon Request https://www.factmr.com/connectus/sample?flag=RM&rep_id=4744

Genetic testing services Market Segmentations type:

By Product Type:

By End-User:

By Region:

Why Choose Fact.MR?

Fact.MR follows a multi- disciplinary approach to extract information about various industries. Our analysts perform thorough primary and secondary research to gather data associated with the market. With modern industrial and digitalization tools, we provide avant-garde business ideas to our clients. We address clients living in across parts of the world with our 24/7 service availability.

Contact:

Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,

Jumeirah Lakes Towers, Dubai, United Arab Emirates

MARKET ACCESS DMCC Initiative

Email: sales@factmr.com

Web: https://www.factmr.com/

Read the original:
New Fact.MR Report: Impact of COVID-19 Crisis on Genetic Testing Services Market Production and Demand 2020 2025 - The Cloud Tribune

Editors note: You might have heard that being pregnant, trying to get pregnant, or delivering right about now is strange, in this age of coronavirus. But how? In what ways? Were going to show you -- with a different persons experience each week. To contribute your own story, scroll all the way to the bottom of this article and tap the link.

Going though in vitro fertilization, or IVF, under normal circumstances, can be a challenge, both mentally and physically -- and for some, thats phrasing it mildly.

Youre going in for bloodwork, sometimes every other day. Youre attending never-ending doctors appointments. Theres a ton on your mind and you just want everything to go well. Its an often-heavy process.

Take it from Sarah*, who asked that we not use her real name, for privacy reasons. Sarah is 32, married, and lives in Farmington Hills, Michigan. She didnt mince words when it came to describing her own IVF situation. Some examples:

Ugh. No one wants to hear of another human going through something like that.

So imagine then, that your support person, like in Sarahs case, her husband, is now unable to attend any of those painful procedures or appointments.

Its scary, Sarah said.

Its also unprecedented. Safe to say, no one assumed the globe would be gripped by a pandemic this year; a true health crisis -- and no one knows when things will return to normal.

But dont get her wrong: Sarah is grateful that shes able to proceed with IVF -- which, spoiler alert, she is. (More on that soon!)

She even added that the couple has decent insurance, and said for many, theyre not so lucky. Most insurance companies dont cover things like IVF, which can total as much as $40,000 for just one round.

But all that money talk, that feels stressful, too. Sarah said if she were to contract COVID-19, her cycle would be canceled. Thats a frightening thought, lingering over ones head.

So then youd be out money, time and pain, Sarah said. (Its like), is it worth it to be doing this?

Sarah has been knee-deep in all things IVF-related for much of the year. She began the journey and went through round one starting in February.

First up, she had two to three weeks of injections, to hopefully produce more eggs.

Sarah took the injections, and then doctors performed a surgery to retrieve her eggs. She said she got through it just fine.

Next, this is typically the time when, if you had any embryos that made it through the egg-retrieval process, the doctors will mix them with sperm, and then youd transfer.

For Sarah, this was when COVID-19 arrived in the United States and started becoming more and more of a growing concern.

She and her husband had ended up with one embryo, so the next step would be a second surgery to make sure nothing is blocking the implantation of said embryo.

But COVID hit right when I was scheduled to go in, Sarah said. So we decided to postpone (and) see how things would play out.

That felt frustrating for the couple, too.

Theyve been playing the waiting game for a long time -- married 6 years, and trying for a baby for about four of those years.

And we dont have a lot of time to wait, Sarah said. We dont want the issues (that led us to IVF in the first place) to get any worse, and were not getting any younger.

Sarah and her husband opted to move forward with the second surgery.

And with the coronavirus pandemic continuing, You had to go through it alone, when youre already scared, Sarah said.

Doctors were able to perform the transfer, but Sarahs husband wasnt allowed to attend.

The whole process is devastating, Sarah said. Youre getting ready to conceive a child and your husband cant even be there.

It was already a tense time.

Then, the couple learned that their embryo transfer failed.

You want answers right away, Sarah said. But doctors arent meeting. So you need to wait for a Zoom call. Youre not being able to see your results and youre not being able to get answers.

Having to survive the failed transfer during quarantine was really tough.

Most doctors (tell you) to stay busy and lean on your support system during all (the waiting), Sarah said.

Because indeed, there is a lot of waiting. More than you might imagine.

(When it comes to) waiting for results in IVF, theres waiting a week to find out if you were able to get any embryos after the first round of injections and egg retrieval surgery, Sarah said. (Then you wait) another two weeks after that for genetic testing on those embryos to see if they are viable, and then of course, the two weeks waiting to find out if youre pregnant after the embryo transfer to see if all your efforts worked.

And, considering coronavirus, Sarah said, all of the now-solo waiting felt especially challenging.

Youre just trapped at home and not able to stay busy to keep yourself mentally healthy, she recalled. I know for me, my friends and family have been my rock during these four years leading to IVF. ... Its been so hard, being isolated.

In discussing the future with Sarah, she sounds optimistic: Theres something cheerful in her tone, and shes so willing to open up and chat about all of this with a total stranger (editors note: which I so admire!)

She and her husband will try again. In fact, theyre set to start a second round of IVF in September.

Her husband has been one of her only comforts throughout this strange time, Sarah said, so she hopes she can have him present for more in-person appointments and procedures this time around. But the future remains incredibly uncertain.

We dont know whats going to happen, Sarah said. In an ideal world, Id probably wait. But with time constraints, you have to try.

Sarah and her husband will likely hole up a bit, leading up to their second IVF round. Luckily, they both have jobs that allow them to work from home. Its a seemingly small perk, but it becomes quite notable through all of this.

And then two weeks or so before the cycle, Sarah said, itll start: Theyll be extra cautious and they wont leave the house until its all over. Too much is at stake.

It makes sense.

Sarah said she wants to help show a different perspective when it comes to pregnancy.

After all, shes had just as many doctors appointments and stressors, if not more, than your average expecting mother.

I hope it helps others who are in the same boat, she said.

Here is the original post:
My (hopeful) pandemic pregnancy: Inside the world of IVF and COVID-19 -- Its terrifying' - KSAT San Antonio

Genes and Ovarian Cancer

Diagnosing ovarian cancer can involve a number of tests, including a physical exam, ultrasound, and blood tests. Genetic testing is also an important part of the diagnostic process, helping to not only detect ovarian cancers, but also find the right treatment for them.

About 15% of ovarian cancers are linked to gene changes called mutations that can be passed down through families. The most common genetic cause of ovarian cancer is a mutation in the BRCA1 or BRCA2 gene. These genes help to repair damaged DNA, and ensure the stability of the cells genetic material. If either of these genes is mutated, DNA damage continues to the point where it can eventually cause the cells to turn cancerous.

Most people who carry a BRCA gene mutation dont realize they have it until someone in their family is diagnosed with cancer. This is why its important for any new diagnosis of ovarian cancer to undergo genetic testing, to see if they are, in fact, a carrier, says Dr. Adam ElNaggar, a gynecologic oncologist at West Cancer Center in Memphis, Tennessee.

Certain groups of people, like Ashkenazi Jews or those whose families originated in Mediterranean countries, are especially susceptible to these mutations. Anyone with a family history of breast or ovarian cancer should ask their doctor about getting tested. Carrying one of the BRCA genes puts you at increased risk not only for ovarian cancer, but also for breast cancer and for other, less common cancers, Dr. ElNaggar says. Knowing your status could help you and your family stay on top of screenings for these other cancers, too.

Although guidelines recommend that all women with ovarian cancer have genetic testing when theyre diagnosed, only a small percentageof women actually do get tested, research finds. Regardless of your age or the type of ovarian cancer you have, testing should be part of your diagnosis.Besides providing valuable information to help your doctor decide on the best treatment for your cancer, knowing that you carry a genetic mutation is valuable for other family members, too. Your immediate family may also benefit from genetic testing. If they find they carry a BRCA1 or BRCA2 mutation it may be recommended that they begin undergoing more frequent screening tests for breast and ovarian cancer, and possibly even consider prophylactic surgery to avoid developing advanced cancer.

Gene mutations not only increase the risk of developing ovarian cancer, but they also can make certain types of treatments, like PARP inhibitor drugsmore effective. PARP is an enzyme that cells normally use to repair their damaged DNA. PARP inhibitors block this enzyme to prevent ovarian cancers with BRCA mutations from fixing DNA damage.

Three PARP inhibitors are approved to treat ovarian cancer:

Some women with ovarian cancer have another genetic marker called homologous recombination deficiency (HRD) that makes them particularly good candidates for PARP inhibitors. Ovarian cancers with HRD are already less able to repair their DNA damage, making them easier for the drugs to fight.

If you picture your DNA like a railroad track, there are two beams, as well as the cross lattice of woodwork, Dr. El Naggar says. When a section of that is taken out, your HRD genes would have come in and put that track back together, repairing both tracks. However, when theyre deficient, the body is unable to do that.

When only one track is broken in other words, one strand of DNA PARP enzymes come in and fix the damage so the cancer cell can keep growing. PARP inhibitors block that repair process which prevents the cancer cells from replicating spreading.

Data shows that PARP inhibitors can have the best results in women with a BRCA mutation or HRD, but new studies show that one PARP inhibitor, niraparib (brand name ZEJULA) may provide some benefit for women without these mutations, as well. These drugs can be used initially with chemotherapy and surgery in what is called first-line treatment, or as maintenance therapy to prevent the cancer from returning after treatment.

Genetic testing can benefit you if youve been diagnosed with ovarian cancer, by helping your doctor determine whether a treatment like a PARP inhibitor is likely to be effective against your cancer. It can also inform your family members, enabling them to be more diligent about getting genetic testing and cancer screening.

Learn more about SurvivorNet's rigorous medical review process.

Dr. Adam ElNaggar is an assistant professor of gynecologic oncology at the University of Tennessee Health Science Center (UTHSC), and director of gynecologic cancer research at the West Cancer Center.Hisclinical interests include personalized medicine, advanced surgical techniques, and targeted therapies. Read More

About 15% of ovarian cancers are linked to gene changes called mutations that can be passed down through families. The most common genetic cause of ovarian cancer is a mutation in the BRCA1 or BRCA2 gene. These genes help to repair damaged DNA, and ensure the stability of the cells genetic material. If either of these genes is mutated, DNA damage continues to the point where it can eventually cause the cells to turn cancerous.

Certain groups of people, like Ashkenazi Jews or those whose families originated in Mediterranean countries, are especially susceptible to these mutations. Anyone with a family history of breast or ovarian cancer should ask their doctor about getting tested. Carrying one of the BRCA genes puts you at increased risk not only for ovarian cancer, but also for breast cancer and for other, less common cancers, Dr. ElNaggar says. Knowing your status could help you and your family stay on top of screenings for these other cancers, too.

Although guidelines recommend that all women with ovarian cancer have genetic testing when theyre diagnosed, only a small percentageof women actually do get tested, research finds. Regardless of your age or the type of ovarian cancer you have, testing should be part of your diagnosis.Besides providing valuable information to help your doctor decide on the best treatment for your cancer, knowing that you carry a genetic mutation is valuable for other family members, too. Your immediate family may also benefit from genetic testing. If they find they carry a BRCA1 or BRCA2 mutation it may be recommended that they begin undergoing more frequent screening tests for breast and ovarian cancer, and possibly even consider prophylactic surgery to avoid developing advanced cancer.

Gene mutations not only increase the risk of developing ovarian cancer, but they also can make certain types of treatments, like PARP inhibitor drugsmore effective. PARP is an enzyme that cells normally use to repair their damaged DNA. PARP inhibitors block this enzyme to prevent ovarian cancers with BRCA mutations from fixing DNA damage.

Three PARP inhibitors are approved to treat ovarian cancer:

Some women with ovarian cancer have another genetic marker called homologous recombination deficiency (HRD) that makes them particularly good candidates for PARP inhibitors. Ovarian cancers with HRD are already less able to repair their DNA damage, making them easier for the drugs to fight.

If you picture your DNA like a railroad track, there are two beams, as well as the cross lattice of woodwork, Dr. El Naggar says. When a section of that is taken out, your HRD genes would have come in and put that track back together, repairing both tracks. However, when theyre deficient, the body is unable to do that.

When only one track is broken in other words, one strand of DNA PARP enzymes come in and fix the damage so the cancer cell can keep growing. PARP inhibitors block that repair process which prevents the cancer cells from replicating spreading.

Data shows that PARP inhibitors can have the best results in women with a BRCA mutation or HRD, but new studies show that one PARP inhibitor, niraparib (brand name ZEJULA) may provide some benefit for women without these mutations, as well. These drugs can be used initially with chemotherapy and surgery in what is called first-line treatment, or as maintenance therapy to prevent the cancer from returning after treatment.

Genetic testing can benefit you if youve been diagnosed with ovarian cancer, by helping your doctor determine whether a treatment like a PARP inhibitor is likely to be effective against your cancer. It can also inform your family members, enabling them to be more diligent about getting genetic testing and cancer screening.

Learn more about SurvivorNet's rigorous medical review process.

Dr. Adam ElNaggar is an assistant professor of gynecologic oncology at the University of Tennessee Health Science Center (UTHSC), and director of gynecologic cancer research at the West Cancer Center.Hisclinical interests include personalized medicine, advanced surgical techniques, and targeted therapies. Read More

Originally posted here:
The Important Role of Genetics in Ovarian Cancer Treatment - SurvivorNet

Overview for Breast Cancer Predictive Genetic Testing Market Helps in providing scope and definitions, Key Findings, Growth Drivers, and Various Dynamics.

The Breast Cancer Predictive Genetic Testing market is expected to grow from USD X.X million in 2020 to USD X.X million by 2026, at a CAGR of X.X% during the forecast period. The global Breast Cancer Predictive Genetic Testing market report is a comprehensive research that focuses on the overall consumption structure, development trends, sales models and sales of top countries in the global Breast Cancer Predictive Genetic Testing market. The report focuses on well-known providers in the global Breast Cancer Predictive Genetic Testing industry, market segments, competition, and the macro environment.

Under COVID-19 Outbreak, how the Breast Cancer Predictive Genetic Testing Industry will develop is also analyzed in detail in Chapter 1.7 of the report.In Chapter 2.4, we analyzed industry trends in the context of COVID-19.In Chapter 3.5, we analyzed the impact of COVID-19 on the product industry chain based on the upstream and downstream markets.In Chapters 6 to 10 of the report, we analyze the impact of COVID-19 on various regions and major countries.In chapter 13.5, the impact of COVID-19 on the future development of the industry is pointed out.

A holistic study of the market is made by considering a variety of factors, from demographics conditions and business cycles in a particular country to market-specific microeconomic impacts. The study found the shift in market paradigms in terms of regional competitive advantage and the competitive landscape of major players.

Download PDF Sample of Breast Cancer Predictive Genetic Testing Market report @ https://www.arcognizance.com/enquiry-sample/1196631

Key players in the global Breast Cancer Predictive Genetic Testing market covered in Chapter 4:OncoCyte CorporationMyriad GeneticsThermo Fisher ScientificQuest DiagnosticsCancer GeneticsInvitaePerkinElmerNeoGenomicsRocheIverson Genetics

In Chapter 11 and 13.3, on the basis of types, the Breast Cancer Predictive Genetic Testing market from 2015 to 2026 is primarily split into:High Penetrant GenesIntermediate Penetrant GenesLow Penetrant Genes

In Chapter 12 and 13.4, on the basis of applications, the Breast Cancer Predictive Genetic Testing market from 2015 to 2026 covers:HospitalsClinicsOther

Brief about Breast Cancer Predictive Genetic Testing Market Report with [emailprotected] https://www.arcognizance.com/report/global-breast-cancer-predictive-genetic-testing-market-report-2020-by-key-players-types-applications-countries-market-size-forecast-to-2026-based-on-2020-covid-19-worldwide-spread

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2015-2026) of the following regions are covered in Chapter 5, 6, 7, 8, 9, 10, 13:North America (Covered in Chapter 6 and 13)United StatesCanadaMexicoEurope (Covered in Chapter 7 and 13)GermanyUKFranceItalySpainRussiaOthersAsia-Pacific (Covered in Chapter 8 and 13)ChinaJapanSouth KoreaAustraliaIndiaSoutheast AsiaOthersMiddle East and Africa (Covered in Chapter 9 and 13)Saudi ArabiaUAEEgyptNigeriaSouth AfricaOthersSouth America (Covered in Chapter 10 and 13)BrazilArgentinaColumbiaChileOthers

Years considered for this report:Historical Years: 2015-2019Base Year: 2019Estimated Year: 2020Forecast Period: 2020-2026

Single User License Copy and Other Purchase [emailprotected] https://www.arcognizance.com/purchase/1196631

Some Point of Table of Content:

Chapter One: Report Overview

Chapter Two: Global Market Growth Trends

Chapter Three: Value Chain of Breast Cancer Predictive Genetic Testing Market

Chapter Four: Players Profiles

Chapter Five: Global Breast Cancer Predictive Genetic Testing Market Analysis by Regions

Chapter Six: North America Breast Cancer Predictive Genetic Testing Market Analysis by Countries

Chapter Seven: Europe Breast Cancer Predictive Genetic Testing Market Analysis by Countries

Chapter Eight: Asia-Pacific Breast Cancer Predictive Genetic Testing Market Analysis by Countries

Chapter Nine: Middle East and Africa Breast Cancer Predictive Genetic Testing Market Analysis by Countries

Chapter Ten: South America Breast Cancer Predictive Genetic Testing Market Analysis by Countries

Chapter Eleven: Global Breast Cancer Predictive Genetic Testing Market Segment by Types

Chapter Twelve: Global Breast Cancer Predictive Genetic Testing Market Segment by Applications12.1 Global Breast Cancer Predictive Genetic Testing Sales, Revenue and Market Share by Applications (2015-2020)12.1.1 Global Breast Cancer Predictive Genetic Testing Sales and Market Share by Applications (2015-2020)12.1.2 Global Breast Cancer Predictive Genetic Testing Revenue and Market Share by Applications (2015-2020)12.2 Hospitals Sales, Revenue and Growth Rate (2015-2020)12.3 Clinics Sales, Revenue and Growth Rate (2015-2020)12.4 Other Sales, Revenue and Growth Rate (2015-2020)

Chapter Thirteen: Breast Cancer Predictive Genetic Testing Market Forecast by Regions (2020-2026)continued

To Check Discount of Breast Cancer Predictive Genetic Testing Market @ https://www.arcognizance.com/discount/1196631

List of tablesList of Tables and FiguresTable Global Breast Cancer Predictive Genetic Testing Market Size Growth Rate by Type (2020-2026)Figure Global Breast Cancer Predictive Genetic Testing Market Share by Type in 2019 & 2026Figure High Penetrant Genes FeaturesFigure Intermediate Penetrant Genes FeaturesFigure Low Penetrant Genes FeaturesTable Global Breast Cancer Predictive Genetic Testing Market Size Growth by Application (2020-2026)Figure Global Breast Cancer Predictive Genetic Testing Market Share by Application in 2019 & 2026Figure Hospitals DescriptionFigure Clinics DescriptionFigure Other DescriptionFigure Global COVID-19 Status OverviewTable Influence of COVID-19 Outbreak on Breast Cancer Predictive Genetic Testing Industry DevelopmentTable SWOT AnalysisFigure Porters Five Forces AnalysisFigure Global Breast Cancer Predictive Genetic Testing Market Size and Growth Rate 2015-2026Table Industry NewsTable Industry PoliciesFigure Value Chain Status of Breast Cancer Predictive Genetic TestingFigure Production Process of Breast Cancer Predictive Genetic TestingFigure Manufacturing Cost Structure of Breast Cancer Predictive Genetic TestingFigure Major Company Analysis (by Business Distribution Base, by Product Type)Table Downstream Major Customer Analysis (by Region)Table OncoCyte Corporation ProfileTable OncoCyte Corporation Production, Value, Price, Gross Margin 2015-2020Table Myriad Genetics ProfileTable Myriad Genetics Production, Value, Price, Gross Margin 2015-2020Table Thermo Fisher Scientific ProfileTable Thermo Fisher Scientific Production, Value, Price, Gross Margin 2015-2020Table Quest Diagnostics ProfileTable Quest Diagnostics Production, Value, Price, Gross Margin 2015-2020Table Cancer Genetics ProfileTable Cancer Genetics Production, Value, Price, Gross Margin 2015-2020Table Invitae ProfileTable Invitae Production, Value, Price, Gross Margin 2015-2020Table PerkinElmer ProfileTable PerkinElmer Production, Value, Price, Gross Margin 2015-2020Table NeoGenomics ProfileTable NeoGenomics Production, Value, Price, Gross Margin 2015-2020Table Roche ProfileTable Roche Production, Value, Price, Gross Margin 2015-2020Table Iverson Genetics ProfileTable Iverson Genetics Production, Value, Price, Gross Margin 2015-2020Figure Global Breast Cancer Predictive Genetic Testing Sales and Growth Rate (2015-2020)Figure Global Breast Cancer Predictive Genetic Testing Revenue ($) and Growth (2015-2020)Table Global Breast Cancer Predictive Genetic Testing Sales by Regions (2015-2020)Table Global Breast Cancer Predictive Genetic Testing Sales Market Share by Regions (2015-2020)Table Global Breast Cancer Predictive Genetic Testing Revenue ($) by Regions (2015-2020)Table Global Breast Cancer Predictive Genetic Testing Revenue Market Share by Regions (2015-2020)Table Global Breast Cancer Predictive Genetic Testing Revenue Market Share by Regions in 2015Table Global Breast Cancer Predictive Genetic Testing Revenue Market Share by Regions in 2019Figure North America Breast Cancer Predictive Genetic Testing Sales and Growth Rate (2015-2020)Figure Europe Breast Cancer Predictive Genetic Testing Sales and Growth Rate (2015-2020)Figure Asia-Pacific Breast Cancer Predictive Genetic Testing Sales and Growth Rate (2015-2020)Figure Middle East and Africa Breast Cancer Predictive Genetic Testing Sales and Growth Rate (2015-2020)Figure South America Breast Cancer Predictive Genetic Testing Sales and Growth Rate (2015-2020)Figure North America Breast Cancer Predictive Genetic Testing Revenue ($) and Growth (2015-2020)Table North America Breast Cancer Predictive Genetic Testing Sales by Countries (2015-2020)Table North America Breast Cancer Predictive Genetic Testing Sales Market Share by Countries (2015-2020)Figure North America Breast Cancer Predictive Genetic Testing Sales Market Share by Countries in 2015Figure North America Breast Cancer Predictive Genetic Testing Sales Market Share by Countries in 2019Table North America Breast Cancer Predictive Genetic Testing Revenue ($) by Countries (2015-2020)Table North America Breast Cancer Predictive Genetic Testing Revenue Market Share by Countries (2015-2020)Figure North America Breast Cancer Predictive Genetic Testing Revenue Market Share by Countries in 2015Figure North America Breast Cancer Predictive Genetic Testing Revenue Market Share by Countries in 2019Figure United States Breast Cancer Predictive Genetic Testing Sales and Growth Rate (2015-2020)Figure Canada Breast Cancer Predictive Genetic Testing Sales and Growth Rate (2015-2020)Figure Mexico Breast Cancer Predictive Genetic Testing Sales and Growth (2015-2020)Figure Europe Breast Cancer Predictive Genetic Testing Revenue ($) Growth (2015-2020)Table Europe Breast Cancer Predictive Genetic Testing Sales by Countries (2015-2020)Table Europe Breast Cancer Predictive Genetic Testing Sales Market Share by Countries (2015-2020)Figure Europe Breast Cancer Predictive Genetic Testing Sales Market Share by Countries in 2015Figure Europe Breast Cancer Predictive Genetic Testing Sales Market Share by Countries in 2019Table Europe Breast Cancer Predictive Genetic Testing Revenue ($) by Countries (2015-2020)Table Europe Breast Cancer Predictive Genetic Testing Revenue Market Share by Countries (2015-2020)Figure Europe Breast Cancer Predictive Genetic Testing Revenue Market Share by Countries in 2015Figure Europe Breast Cancer Predictive Genetic Testing Revenue Market Share by Countries in 2019Figure Germany Breast Cancer Predictive Genetic Testing Sales and Growth Rate (2015-2020)Figure UK Breast Cancer Predictive Genetic Testing Sales and Growth Rate (2015-2020)Figure France Breast Cancer Predictive Genetic Testing Sales and Growth Rate (2015-2020)Figure Italy Breast Cancer Predictive Genetic Testing Sales and Growth Rate (2015-2020)Figure Spain Breast Cancer Predictive Genetic Testing Sales and Growth Rate (2015-2020)Figure Russia Breast Cancer Predictive Genetic Testing Sales and Growth Rate (2015-2020)Figure Asia-Pacific Breast Cancer Predictive Genetic Testing Revenue ($) and Growth (2015-2020)Table Asia-Pacific Breast Cancer Predictive Genetic Testing Sales by Countries (2015-2020)Table Asia-Pacific Breast Cancer Predictive Genetic Testing Sales Market Share by Countries (2015-2020)Figure Asia-Pacific Breast Cancer Predictive Genetic Testing Sales Market Share by Countries in 2015Figure Asia-Pacific Breast Cancer Predictive Genetic Testing Sales Market Share by Countries in 2019Table Asia-Pacific Breast Cancer Predictive Genetic Testing Revenue ($) by Countries (2015-2020)Table Asia-Pacific Breast Cancer Predictive Genetic Testing Revenue Market Share by Countries (2015-2020)Figure Asia-Pacific Breast Cancer Predictive Genetic Testing Revenue Market Share by Countries in 2015Figure Asia-Pacific Breast Cancer Predictive Genetic Testing Revenue Market Share by Countries in 2019Figure China Breast Cancer Predictive Genetic Testing Sales and Growth Rate (2015-2020)Figure Japan Breast Cancer Predictive Genetic Testing Sales and Growth Rate (2015-2020)Figure South Korea Breast Cancer Predictive Genetic Testing Sales and Growth Rate (2015-2020)Figure Australia Breast Cancer Predictive Genetic Testing Sales and Growth Rate (2015-2020)Figure India Breast Cancer Predictive Genetic Testing Sales and Growth Rate (2015-2020)Figure Southeast Asia Breast Cancer Predictive Genetic Testing Sales and Growth Rate (2015-2020)Figure Middle East and Africa Breast Cancer Predictive Genetic Testing Revenue ($) and Growth (2015-2020)continued

If you have any special requirements, please let us know and we will offer you the report as you want.

About Us:Analytical Research Cognizance (ARC)is a trusted hub for research reports that critically renders accurate and statistical data for your business growth. Our extensive database of examined market reports places us amongst the best industry report firms. Our professionally equipped team further strengthens ARCs potential.ARC works with the mission of creating a platform where marketers can have access to informative, latest and well researched reports. To achieve this aim our experts tactically scrutinize every report that comes under their eye.

Contact Us:Ranjeet DengaleDirector SalesAnalytical Research Cognizance+1 (646) 403-4695, +91 90967 44448Email: [emailprotected]

Read the original here:
Impact Of Covid-19 on Breast Cancer Predictive Genetic Testing Market 2020 Industry Challenges, Business Overview and Forecast Research Study 2026 -...

New Jersey, United States Direct-To-Consumer (DTC) Genetic Testing Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2026Presented byVerified Market Researchpresents a broad and elementary study of the market giving point by point coverage of the industry with its major market trends. The report contains the most important industry information while highlighting essential and valuable data. The report highlights inside and out research on market size, the development condition, advancement pattern, activity situation, and future advancement trends of the Direct-To-Consumer (DTC) Genetic Testing Market. It offers learning of various factors like Direct-To-Consumer (DTC) Genetic Testing Market growth, consumption volume, and business price structures throughout the forecast amount from 2020 to 2026. This research will also help makers and venture associations to higher handle the occasion course of the market.

Global Direct-to-Consumer (DTC) Genetic Testing Market was valued at USD 789.92 Million in 2018 and is projected to reach USD 2,361.12 Billion by 2026, growing at a CAGR of 14.59% from 2019 to 2026.

The report is furnished with the latest occurrences in the market owing to the COVID-19 pandemic. The pandemic has brought dynamic changes in the industry and the overall economic scenario. The report covers the impact analysis of the COVID-19 pandemic on market growth and revenue. The report also provides an extensive analysis of the current and future impact of the pandemic and an analysis of the post-COVID-19 scenario. This report includes data producers, including: shipping, pricing, revenues, gross profit, record interviews, business distribution, etc., this data helps consumers know about a better competitor.

Get | Download Sample Copy of this [emailprotected] https://www.verifiedmarketresearch.com/download-sample/?rid=25584&utm_source=BLN&utm_medium=003

The report provides an in-depth analysis of the competitive landscape and covers profiles of key players, along with their product portfolios and business strategies.

Key players of the market mentioned in the report are:

COVID-19 can influence the global economy in three ways: by directly influencing production and demand, by creating supply chain and market disruptions, and by having a financial impact on businesses and financial markets. The eruption of COVID-19 has implications for many aspects such as flight cancellations. Travel bans and quarantines; Restaurants closed; all Indoor Events restricted; over forty countries declared a state of emergency; massive supply chain slowdown; stock market volatility; falling business confidence, growing panic in the population and uncertainty about the future.

Competitive Landscape:

Direct-To-Consumer (DTC) Genetic Testing Market report highlights key players included in the market in order to render a comprehensive view of the competing players existing in the market. Company details, strategies, aptitude, history, cost analysis, and prevalent strategies. This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and Production by manufacturers during the forecast period of 2019 to 2026.

Regional analysis:

Geographically, the global Specialty Frozen Bakery market is divided into global regions like Europe, North America, Asia- Pacific, Middle East and Africa.

Ask For [emailprotected] https://www.verifiedmarketresearch.com/ask-for-discount/?rid=25584&utm_source=BLN&utm_medium=003

Highlights of the TOC of the Global Direct-To-Consumer (DTC) Genetic Testing Market Report:

Scope of Report:

This study analyses the growth of Direct-To-Consumer (DTC) Genetic Testing Market based on the present, past and futuristic data and will render entire information about the Internet Advertising industry to the market-leading industry players that will guide the direction of the Direct-To-Consumer (DTC) Genetic Testing Market through the forecast period. All of these players are analysed in detail to get details concerning their recent announcements and partnerships, product/services, investment strategies, and so on.

The key insights of the Direct-To-Consumer (DTC) Genetic Testing Market report:

Report customization:

Verified Market Research also provides customization options to tailor the reports as per client requirements. This report can be personalized to cater to your research needs. Feel free to get in touch with our sales team, who will ensure that you get a report as per your needs.

Purchase report with detailed assessment of the present and future impact of the COVID-19 pandemic on the industry: https://www.verifiedmarketresearch.com/checkout/?buyreport=25584&utm_source=BLN&utm_medium=003

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals, and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyse data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080

UK: +44 (203)-411-9686

APAC: +91 (902)-863-5784

US Toll-Free: +1 (800)-7821768

Email: [emailprotected]

Thank You for reading our report. The report is available for customization based on chapters or regions. Please get in touch with us to know more about customization options, and our team will ensure you get the report tailored according to your Requirements.

The rest is here:
Direct-To-Consumer (DTC) Genetic Testing Market Overview with Detailed Analysis, Competitive landscape, Forecast to 2027 - Bulletin Line

Ancestry is stepping up its consumer DNA testingusing next-generation sequencing developed by Quest Diagnostics.

The family history and consumer genomics company is relaunching its AncestryHealth service with more advanced genetic testing technology to flag cutsomers' risk for developing certain inheritable diseases.

The sequencing-based tests replace Ancestry'sprevious microarray-based tests, the company said in arelease. The tests are physician-ordered, are not diagnostic and have not beenreviewed or approved by the Food and Drug Administration (FDA).

Top-Rated Mobile App for Health Insurance Members

Ziparis Mobile App is the smarter, easier, and better way for payers to engage members on the go and directly in the palm of their hands. Members can find the right doctors, receive notifications, send messages, view claims, track spending, talk to a nurse, download ID card, and more. Its ready to install and launch in a few months.

The advanced testing technology will help people better understand their risk for developing certain inherited health conditions such as heart disease, breast cancer, colon cancer and blood disorders, Ancestry said.

RELATED:Genealogy company Ancestry launches consumer genetic health testing as a rival to 23andMe

"When it comes to your health and your familys health, the more you know, the better, said Ron Park, M.D. executive vice presidentof health and DNA atAncestry in a statement.

"With the launch of AncestryHealth powered by NGS, we are helping people have access to more comprehensive data about their genetic risksand providing support with understanding those risksat a time when protecting our health is a major concern," Park said.

Ancestry, a company that uses DNA testing to give consumers information about their family history, moved into consumer genetic health testing as a rival to 23andMe last fall.

Ancestry, which owns AncestryDNA and launched in 2002, is one of the largest direct-to-consumer testing companies in the world with 24 billion records and more than 18 million people in its network.

The company saidits relaunched health offeringmarks a dramatic shift in consumer-initiated genetic testing, which, for the last decade, has largely been based on microarray technology.

Because NGS technology can access orders of magnitude more of the genome, including challenging-to-sequence variants, the NGS technology that powers AncestryHealth does a better job of determining if someone is at greater risk for some of the most common inherited health conditions, according to Quest Diagnostics.

RELATED:JPM20: Health technology company Color scores $75M funding round to scale its infrastructure

In comparison to the more widely-used microarray-based testing technology, AncestryHealth powered by next-generation sequencing achieves about 80% to 90% detection of inherited risk for specific health conditions, according to the company.

The use of the technology can lead to higher detection rates for the risk of breast and ovarian cancer, for example, at arate four times higher than most microarray-based tests, Ancestry said.

"As the market leader in consumer genomics for more than a decade, we are proud to make an important leap forward in democratizing access to comprehensive genetic health risk detection, said Margo Georgiadis, president and chief executive officer at Ancestry.

AncestryHealth will provide customers with remote access to genetic counselors in partnership withPWNHealth, an independent network of board-certified genetic counselors, geneticistsand physicians, as well as access to a clinical lab report to share with their doctors.

These services will help consumers better understand their results and make more informed choices, the company said.

Ancestry also aims to create a downloadable family health history record that can be delivered to clinicians and used to help fill out medical forms.

RELATED:Ancestry's Catherine Ball on why the genealogy company just gave UpToDate a $1M grant

Quest developed a faster and cheaper way to perform next generation sequencingto power AncestryHealth, the company said.

"This improvement in automating next generation sequencing will enable genetic screening faster and at much lower cost, and could have profound implications for healthcare in the future, truly empowering better health through actionable insights for millions of people who want to know more about their health risks," saidSteve Rusckowski, Quest Diagnostics chairman, chief executive and president in a statement.

"It wasn't long ago that genetic sequencing took months and cost thousands of dollars. Quest's proprietary innovation enables sequencing insights in a fraction of the time at a fraction of the cost," Rusckowski said.

AncestryHealths kit will be available in 47 states, not including New York, New Jersey and Rhode Island, for $179.

Read the original post:
Ancestry rolls out more advanced DNA testing to flag risk of heart disease, breast cancer - FierceHealthcare

This recent study of the Rare Disease Genetic Testing market contains a thorough evaluation of this industry vertical. According to the report, the market will record decent returns by the end of the forecast period, while registering a substantial growth rate throughout this duration.

Growth Report on Rare Disease Genetic Testing Market size | Industry Segment by Applications (Research Laboratories and CROs, Diagnostic Laboratories, Hospitals and Clinics and Others), by Type (Next-Generation Sequencing (NGS), Array Technology, PCR-based Testing, Fluorescence in Situ Hybridization (FISH), Sanger Sequencing, Karyotyping and Others), Regional Outlook, Market Demand, Latest Trends, Rare Disease Genetic Testing Industry Share, Research Growth Forecast & Revenue by Manufacturers, The Leading Company Profiles, Growth Forecasts 2025.

Request Sample Copy of this Report @ https://www.express-journal.com/request-sample/161113

The report uncovers important insights of the Rare Disease Genetic Testing market and includes projections with respect to revenue, industry size, and sales volumes over the study period. Additionally, the Rare Disease Genetic Testing market report provides detailed information regarding industry segmentations as well as the driving factors that will propel the profitability graph of the industry.

This report studies the Rare Disease Genetic Testing market status and outlook of global and major regions, from angles of players, countries, product types and end industries, this report analyzes the top players in global Rare Disease Genetic Testing industry, and splits by product type and applications/end industries. This report also includes the impact of COVID-19 on the Rare Disease Genetic Testing industry.

A glimpse of the Rare Disease Genetic Testing market with respect to the geographical landscape:

Competitive Landscape and Rare Disease Genetic Testing Market Share Analysis:

Rare Disease Genetic Testing competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Rare Disease Genetic Testing sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Rare Disease Genetic Testing sales, revenue and market share for each player covered in this report.

Market segmentation: Rare Disease Genetic Testing market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Other important inclusions of the Rare Disease Genetic Testing market are listed below:

Research objectives:

Questions Answered by the Report:

Request Customization on This Report @ https://www.express-journal.com/request-for-customization/161113

Continue reading here:
Rare Disease Genetic Testing Market 2020; Region Wise Analysis of Top Players in Market and its Types and Application - Express Journal

News

The RACGP is offering training in carrier screening, covering the knowledge and skills required to initiate the important conversation with patients.

Around one in 200 babies is born with an inherited rare condition.These conditions account for 20% of infant mortality. And while they are individually rare, people on average are carriers of two severe autosomal recessive conditions.While genetic carrier screening has traditionally only been offered to those with a family history and partners of identified carriers, as well as those of a particular ethnicity, that has since changed.National guidelines now recommend all women or couples planning a family, or who are in the first trimester of pregnancy, be given the option in order to understand their risk.To help raise awareness among GPs and other healthcare professionals, the RACGP has launched the Beware the Rare education campaign.Professor Jon Emery is a GP and adviser for the campaign. He says the earlier carrier screening is carried out, the better.This provides couples an opportunity to plan their reproductive choices more into the future, he told newsGP.Part of this campaign is around raising these issues when couples are beginning to plan a pregnancy, so preconception, because the reproductive choices are somewhat greater at that point.But, of course, we know a lot of people will often get pregnant without them necessarily formally planning it, and so the other time to be having these discussions is early on in the first trimester of the pregnancy, and offering the couple the opportunity to consider whether they want to have carrier screening to see if theyre at risk of having an affected child.Modes of testing including either a mouth swab or blood test.There are currently three types of carrier screening panels available:

Professor Jon Emerysays the earlier carrier screening is carried out, the better.Medicare does not currently provide rebates for most genetic tests, which cost patients hundreds of dollars.A research program called Mackenzies Mission is setting out to change that, however, thanks in large part to Rachael Casella and her husband.After losing their seven-month-old daughter Mackenzie in 2017 to spinal muscular atrophy type 1, a genetic neuromuscular disorder, the couple lobbied the Federal Government to make genetic testing routine and covered by Medicare.In response, $20 million was committed from the Medical Research Future Fund to a three-year pilot study that will set out to screen 10,000 Australian couples for around 750 genetic conditions.The expanded panel test costs between $600 and $900. So its not a cheap test, Professor Emery said.Mackenzies Mission will hopefully provide new evidence around the accessibility of this test, and inform future decisions around whether these tests eventually become available through the Federal Government.But I think we are increasingly going to see a greater role for genomic tests, both in terms of reproductive choices, but also in terms of predicting the way we respond to drugs and predicting our risks of a range of common diseases so that we can tailor our prevention more.The RACGP is hosting a free webinar, Fertility, pregnancy and genetic testing options, on Wednesday 5 August, 7.00pm8.00 pm (AEST). The event attracts two CPD points. Visit the RACGP website to register.GPs can access information and resources on genetic carrier screening through the RACGPs education campaign website. There is also an accredited training module worth two CPD points.Log in below to join the conversation.

genetic carrier screening preconception pregnancy reproductive choice

The rest is here:
newsGP - Genetic carrier screening: What GPs need to know - RACGP

Global At-home Genetic Testing Market Report 2019 Market Size, Share, Price, Trend and Forecast is a professional and in-depth study on the current state of the global At-home Genetic Testing industry.

The report also covers segment data, including: type segment, industry segment, channel segment etc. cover different segment market size, both volume and value. Also cover different industries clients information, which is very important for the manufacturers.

There are 4 key segments covered in this report: competitor segment, product type segment, end use/application segment and geography segment.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.marketresearchhub.com/enquiry.php?type=E&repid=2601844&source=atm

For competitor segment, the report includes global key players of At-home Genetic Testing as well as some small players.

The key players covered in this study23andMeMyHeritageLabCorpMyriad GeneticsAncestry.comQuest DiagnosticsGene By GeneDNA Diagnostics CenterInvitaeIntelliGeneticsAmbry GeneticsLiving DNAEasyDNAPathway GenomicsCentrillion TechnologyXcodeColor GenomicsAnglia DNA ServicesAfrican AncestryCanadian DNA ServicesDNA Family CheckAlpha BiolaboratoriesTest Me DNA23 MofangGenetic HealthDNA Services of AmericaShuwen Health SciencesMapmygenomeFull Genomes

Market segment by Type, the product can be split intoDiagnostic ScreeningPGDRelationship testingMarket segment by Application, split intoOnlineOffline

Market segment by Regions/Countries, this report coversNorth AmericaEuropeChinaJapanSoutheast AsiaIndiaCentral & South America

The study objectives of this report are:To analyze global At-home Genetic Testing status, future forecast, growth opportunity, key market and key players.To present the At-home Genetic Testing development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.To strategically profile the key players and comprehensively analyze their development plan and strategies.To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of At-home Genetic Testing are as follows:History Year: 2015-2019Base Year: 2019Estimated Year: 2020Forecast Year 2020 to 2026For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2601844&licType=S&source=atm

Important Key questions answered in At-home Genetic Testing market report:

What will the market growth rate, Overview, and Analysis by Type of At-home Genetic Testing in 2024?

What are the key factors affecting market dynamics? What are the drivers, challenges, and business risks in At-home Genetic Testing market?

What is Dynamics, This Overview Includes Analysis of Scope and price analysis of top Manufacturers Profiles?

Who Are Opportunities, Risk and Driving Force of At-home Genetic Testing market? Knows Upstream Raw Materials Sourcing and Downstream Buyers.

Who are the key manufacturers in space? Business Overview by Type, Applications, Gross Margin, and Market Share

What are the opportunities and threats faced by manufacturers in the global market?

Get PDF Sample Copy of this Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2601844&source=atm

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe At-home Genetic Testing product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top manufacturers of At-home Genetic Testing , with price, sales, revenue and global market share of At-home Genetic Testing in 2019 and 2015.

Chapter 3, the At-home Genetic Testing competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the At-home Genetic Testing breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2019 to 2025.

Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2019 to 2025.

Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2019 to 2025.

Chapter 12, At-home Genetic Testing market forecast, by regions, type and application, with sales and revenue, from 2019 to 2025.

Chapter 13, 14 and 15, to describe At-home Genetic Testing sales channel, distributors, customers, research findings and conclusion, appendix and data source.

Visit link:
At-home Genetic Testing Market Research by Key players, Type and Application, Future Growth to 2026 - Owned

Overview Of Breast Cancer Predictive Genetic Testing Industry 2020-2025:

This has brought along several changes in This report also covers the impact of COVID-19 on the global market.

The Breast Cancer Predictive Genetic Testing Market analysis summary by Reports Insights is a thorough study of the current trends leading to this vertical trend in various regions. Research summarizes important details related to market share, market size, applications, statistics and sales. In addition, this study emphasizes thorough competition analysis on market prospects, especially growth strategies that market experts claim.

Breast Cancer Predictive Genetic Testing Market competition by top manufacturers as follow: , Roche, Thermo Fisher Scientific, PerkinElmer, Quest Diagnostics, Myriad Genetics, Iverson Genetics, Cancer Genetics, OncoCyte Corporation, NeoGenomics, Invitae

Get a Sample PDF copy of the report @ https://reportsinsights.com/sample/114139

The global Breast Cancer Predictive Genetic Testing market has been segmented on the basis of technology, product type, application, distribution channel, end-user, and industry vertical, along with the geography, delivering valuable insights.

The Type Coverage in the Market are: High Penetrant GenesIntermediate Penetrant GenesLow Penetrant Genes

Market Segment by Applications, covers:HospitalsClinicsOthers

Market segment by Regions/Countries, this report coversNorth AmericaEuropeChinaRest of Asia PacificCentral & South AmericaMiddle East & Africa

Major factors covered in the report:

To get this report at a profitable rate.: https://reportsinsights.com/discount/114139

The analysis objectives of the report are:

Access full Report Description, TOC, Table of Figure, Chart, [emailprotected] https://reportsinsights.com/industry-forecast/Breast-Cancer-Predictive-Genetic-Testing-Market-114139

About US:

Reports Insights is the leading research industry that offers contextual and data-centric research services to its customers across the globe. The firm assists its clients to strategize business policies and accomplish sustainable growth in their respective market domain. The industry provides consulting services, syndicated research reports, and customized research reports.

Contact US:

:(US) +1-214-272-0234

:(APAC) +91-7972263819

Email:[emailprotected]

Sales:[emailprotected]

Go here to read the rest:
New Comprehensive Report on Breast Cancer Predictive Genetic Testing Market to Witness an Outstanding Growth during 2020 2025 with Top Players Like...

Predictive Genetic Testing And Consumer/Wellness Genomics Market research is an intelligence report with meticulous efforts undertaken to study the right and valuable information. The data which has been looked upon is done considering both, the existing top players and the upcoming competitors. Business strategies of the key players and the new entering market industries are studied in detail. Well explained SWOT analysis, revenue share and contact information are shared in this report analysis.

Predictive Genetic Testing And Consumer/Wellness Genomics Market is growing at a High CAGR during the forecast period 2020-2026. The increasing interest of the individuals in this industry is that the major reason for the expansion of this market.

Get Sample Copy (Including FULL TOC, Graphs and Tables) of this report:

https://www.a2zmarketresearch.com/sample?reportId=115261

Top Key Players Profiled in This Report:

Illumina, BGI, Genesis Genetics, Myriad Genetics, 23andMe, Inc, Color Genomics Inc, Pathway Genomics, ARUP Laboratories

The key questions answered in this report:

Various factors are responsible for the markets growth trajectory, which are studied at length in the report. In addition, the report lists down the restraints that are posing threat to the global Predictive Genetic Testing And Consumer/Wellness Genomics market. It also gauges the bargaining power of suppliers and buyers, threat from new entrants and product substitute, and the degree of competition prevailing in the market. The influence of the latest government guidelines is also analyzed in detail in the report. It studies the Predictive Genetic Testing And Consumer/Wellness Genomics markets trajectory between forecast periods.

Get up to 20% Discount on this Premium Report @:

https://www.a2zmarketresearch.com/discount?reportId=115261

Reasons for buying this report:

Table of Contents:

Global Predictive Genetic Testing And Consumer/Wellness Genomics Market Research Report

Chapter 1 Predictive Genetic Testing And Consumer/Wellness Genomics Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Global Predictive Genetic Testing And Consumer/Wellness Genomics Market Forecast

Buy Exclusive Report @:

https://www.a2zmarketresearch.com/buy?reportId=115261

If you have any special requirements, please let us know and we will offer you the report as you want.

Go here to read the rest:
Comprehensive Report on Predictive Genetic Testing And Consumer/Wellness Genomics Market 2020 | Size, Growth, Demand, Opportunities & Forecast To...

The recent research report titled Global (Covid-19 Impact) Breast Cancer Predictive Genetic Testing Sales Market (Sales,Revenue and competitors Analysis of Major Market) from 2014-2026 has been added in the kandjmarketresearch.com database. This market report is a valuable source of insightful data for business strategists. It offers the industry overview with growth analysis and historical & futuristic cost, revenue, demand, and supply data (as applicable). The report explores the current outlook in global and key regions from the perspective of players, countries, product types, and end industries. This Breast Cancer Predictive Genetic Testing Market study provides comprehensive data that enhances the understanding, scope, and application of this report.

Market Overview

Indispensable insights of the Breast Cancer Predictive Genetic Testing market are elaborated in the report. The core objective of the report is to deliver reliable and concrete information about the Breast Cancer Predictive Genetic Testing market that can assist the businessmen to make rational decisions. The expected CAGR and valuation of the Breast Cancer Predictive Genetic Testing market are mentioned in the report. Proficient analysts have studied the market for the evaluation year of 2020 to 2026. Significant factors that are likely to promote the growth of the Breast Cancer Predictive Genetic Testing market and possible constraints of the market are elaborated in this market research report. Potential growth scopes are also elaborated in the report. The Breast Cancer Predictive Genetic Testing market studied in segments to provide information about the same market that encompasses crucial aspects of the Breast Cancer Predictive Genetic Testing industry or market. The regional progress of the Breast Cancer Predictive Genetic Testing market is studied under the regional outlook section. A lucid understanding of the transforming competitive landscape of the market can assist investors in several ways. North America, Europe, and APAC are key regions across which is in the studied. For the Rest of the World (RoW), the Breast Cancer Predictive Genetic Testing market is analyzed across China, USA, Europe, Japan, Korea, India, Southeast Asia and South America.

The latest report includes Impact of Coronavirus(Covid-19) on the Breast Cancer Predictive Genetic Testing Industry, it includes on Industry Upstream, Industry Downstream, Industry Channels, Industry Competition, and finally on Industry Employment.

The Final Report Will Include the Impact of COVID 19 Analyses in This Industry. For Sample Report & Graphs & Charts @: https://www.kandjmarketresearch.com/sample-request/403987

Key Players overview

Credible sources, such as surveys, financial magazines, and whitepapers are referred for listing key players of the Breast Cancer Predictive Genetic Testing market. However, interviews with well-known personalities, such as CEOs, COO, and entrepreneurs are accepted as the most effective tool to prepare contribution of key players towards the growth of the Breast Cancer Predictive Genetic Testing market. Past aspects and current trends of market players in the Breast Cancer Predictive Genetic Testing market are elaborated in the report. The financial status of market players and their contributions are discussed in the report that offers a clear understanding to the investors and aids them in making rational decisions.

Global Breast Cancer Predictive Genetic Testing market competition by top manufacturers/players, with Breast Cancer Predictive Genetic Testing sales volume, Price (USD/Unit), revenue (M USD) and market share for each manufacturer/player; the top players including:

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into:-

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Breast Cancer Predictive Genetic Testing for each application, including:-

Ask for Discount @https://www.kandjmarketresearch.com/discount/403987

This report split global into several key Regions, with sales (K Units), revenue (M USD), market share and growth rate of Breast Cancer Predictive Genetic Testing for these regions, from 2014 to 2026 (forecast), covering:-

Research Methodology

Research methodologies utilized in cooking the report are rigorous and fail-safe. The robust scoring process is employed to deliver an objective and accurate overview of the Breast Cancer Predictive Genetic Testing market. Modern research techniques used to offer vivid qualitative and qualitative findings of the Breast Cancer Predictive Genetic Testing industry. The powerful research techniques used to study the Breast Cancer Predictive Genetic Testing market aid in the collection of evidence and data to deliver precise report. The market research firm uses various tools for the collection of information for primary and secondary analysis of the Breast Cancer Predictive Genetic Testing market to prepare a report that can be an ultimate guide for investors. Top-down and bottom-up approaches maintained for the assessment of the Breast Cancer Predictive Genetic Testing market for the forecast years ensures high-quality and valuable insights into the Breast Cancer Predictive Genetic Testing market.

Key Highlights of TOC:

And List of Tables and Figures.

Read More Detailed Information regarding Breast Cancer Predictive Genetic Testing Industry with Covid-19 Updates @ https://www.kandjmarketresearch.com/reports/403987-global-covid-19-impactbreast-cancer-predictive-genetic-testing-sales-market-salesrevenue-and-competitors-analysis-of-major-market-from-2014-2026

About Us:

Kandjmarketresearch.com is part of the KnowledgeNJournals Research Firm which provides premium progressive market research reports, statistical surveying, analysis & forecast data for industries and governments from hundreds of publishers around the world. We have almost all top publishers reports in our collection to provide you with instant online access to the worlds most complete and fresh database on a Daily Basis. We are at KandJ Market Research are inspired to help our clients grow by providing appropriate business insight with our huge market intelligence source.

If you have any special requirements for the report, please let us know and we will offer you a customized report on separate regional or country-level reports.

Contact us:

KandJ Market Research

(Part of KnowledgeNJournals Research)

E-mail: [emailprotected]

Website: https://www.kandjmarketresearch.com

(USA): +1 661 636 6162 | (IND): +91 932 580 2062

Continued here:
Breast Cancer Predictive Genetic Testing Market 2020-2026 Analysis, Trends And Forecasts Research Report - Owned

The prime objective of GlobalNewborn and Prenatal Genetic Testing Market report is to help the user understand the market in terms of its definition, segmentation, market potential, influential trends, and the challenges that the market is facing with 10 major regions and 30 major countries. Deep researches and analysis were done during the preparation of the report. The readers will find this report very helpful in understanding the market in depth. The data and the information regarding the market are taken from reliable sources such as websites, annual reports of the companies, journals, and others and were checked and validated by the industry experts. The facts and data are represented in the report using diagrams, graphs, pie charts, and other pictorial representations. This enhances the visual representation and also helps in understanding the facts much better.

Impact of Covid-19 in Newborn and Prenatal Genetic Testing Market: Report covers Impact of Coronavirus COVID-19: Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost every country around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Newborn and Prenatal Genetic Testing market in 2020. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor/outdoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.

Download FREE Sample Copy of Newborn and Prenatal Genetic Testing Report @https://www.crediblemarkets.com/sample-request/newborn-and-prenatal-genetic-testing-market-51974

By Market Players:Perkin ElmerAriosa DiagnosticsAgilent Technologies, Inc.Verinata HealthIllumina, Inc.Sequenom, Inc.CapitalBio MedLabNatera, Inc.Bio-Rad Laboratories, Inc.BGI

By TypePCRFISHaCGHNIPTMSS

By ApplicationHospitalClinicOthers

Geographically, the detailed analysis of consumption, revenue, and market share and growth rate, historic and forecast of the following regions:

United States, Canada, Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden, Poland, Belgium, China, Japan, South Korea, Australia, India, Taiwan, Indonesia, Thailand, Philippines, Malaysia, Brazil, Mexico, Argentina, Columbia, Chile, Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of the World

Enquiry before buying this report @ https://www.crediblemarkets.com/enquire-request/newborn-and-prenatal-genetic-testing-market-51974

Some Points from Table of Content

Covid-19 Impact on Global Newborn and Prenatal Genetic Testing Industry Research Report 2020 Segmented by Major Market Players, Types, Applications and Countries Forecast to 2026

Chapter 1 Report OverviewChapter 2 Global Newborn and Prenatal Genetic Testing Market Trends and Growth StrategyChapter 3 Global Newborn and Prenatal Genetic Testing Market Players ProfilesChapter 4 Global Newborn and Prenatal Genetic Testing Market Competition by Market PlayersChapter 5 Global Newborn and Prenatal Genetic Testing Production by Regions (2015-2020)Chapter 6 Global Newborn and Prenatal Genetic Testing Consumption by Region (2015-2020)Chapter 7 Global Newborn and Prenatal Genetic Testing Production Forecast by Regions (2021-2026)Chapter 8 Global Newborn and Prenatal Genetic Testing Consumption Forecast by Regions (2021-2026)Chapter 9 Global Newborn and Prenatal Genetic Testing Sales by Type (2015-2026)Chapter 10 Global Newborn and Prenatal Genetic Testing Consumption by Application (2015-2026)Chapter 11 Global Newborn and Prenatal Genetic Testing Manufacturing Cost AnalysisChapter 12 Global Newborn and Prenatal Genetic Testing Marketing Channel, Distributors, Customers and Supply ChainChapter 13 Analysts Viewpoints/ConclusionsChapter 14 Disclaimer

Grab Maximum Discount on Newborn and Prenatal Genetic Testing Market Research Report @https://www.crediblemarkets.com/discount-request/newborn-and-prenatal-genetic-testing-market-51974

Points Covered in The Report

About Credible Markets

Credible Markets has emerged as a dependable source for the market research needs of businesses within a quick time span. We have collaborated with leading publishers of market intelligence and the coverage of our reports reserve spans all the key industry verticals and thousands of micro markets. The massive repository allows our clients to pick from recently published reports from a range of publishers that also provide extensive regional and country-wise analysis. Moreover, pre-booked research reports are among our top offerings.

Contact Us

Credible Markets Analytics

99 Wall Street 2124 New York, NY 10005

US Contact No: +1(929)-450-2887

Email: [emailprotected]

Ask for customization @https://www.crediblemarkets.com/custom-research

The rest is here:
Newborn and Prenatal Genetic Testing Market 2020 Segmented by Major Market Players, Types, Applications and Countries Forecast to 2026 - Bulletin Line

This article concerns the development of advanced therapies and the challenges and complexities of getting them through the developmental pathway, which the authors call the trip. The authors examine at strategic levels the importance of some of the fundamental building blocks for the development program and highlight some commonly encountered challenges (trip hazards) for cell and gene therapies and offer bench-to-bedside and chemistry, manufacturing, and controls (CMC) considerations and advise on nonclinical and clinical investigations. They conclude that early contact with regulators can help avoid trip hazards.IntroductionThe advanced therapy sector has grown rapidly, reflecting the tremendous interest for these complex biologic products with potentially curative effect. Advanced therapy products, including cell and gene therapies, as well as tissue-engineered products, have shown great promise for addressing medically unmet needs, particularly for orphan diseases and in oncology. The Alliance for Regenerative Medicine reported a 32% growth in clinical investigations of regenerative medicine products from 2014 to 2018.1 Currently, there are more than 2,000 product candidates under development. Although forecasts of compound annual growth rates and predicted market values vary among different reports, the cell and gene therapy market was valued at more than US$1 billion in 2018 and by 2025, is likely to exceed US$10 billion.2However, product development for advanced therapies still poses a number of potential trip hazards, even though supporting guidance has matured to a good level. Potential challenges may occur at all stages of nonclinical, process, and clinical product development. These hazards include, but not limited to, technology transfer; CMC; clinical investigations; and stage-appropriate good practice considerations. It is paramount to be aware of trip hazards before they occur, because they can equate to time- and cost-related program impacts.In this article we will highlight, at a strategic level, the importance of some of the fundamental building blocks for the development program and highlight some commonly encountered challenges (trip hazards) for cell and gene therapies, in which things frequently go wrong, and sometimes critically so. For simplicity, tissue-engineered products are not covered in the scope of this article but share certain commonality with cellular-based products.What makes advanced therapies different?It is imperative to understand the product itself for the successful development of any therapeutic product. Small molecules are very well understood because they are a single molecule of low-molecular weight and produced through a defined chemical synthesis that yields mathematically identical copies. As such, they can be straightforwardly characterized. Biologics, such as monoclonal antibodies, cytokines, and other recombinant products, can also be generally well defined but they have higher structural complexity and posttranslational modifications. The fact that these are manufactured in living producer cells also reduces the ability to control production of identical copies. There is, therefore, inherent heterogeneity in the product, making biologics generally more sensitive to external conditions and stability. Many of the traits associated with biologics also apply to advanced therapies. So, what makes them so different?Advanced therapies add an additional layer of complexity to the traditional biologic product. These definitions are paraphrased from the European Medicines Agency (EMA)3 and US Food and Drug Administration (FDA)4 definitions for cell and gene therapies:

CMC considerationsProduct diversity is a key point for understanding advanced therapies in that there is greater multiplicity of cellular/gene/tissue products. Therefore, a one-size-fits-all approach does not work precisely, with there often being specific and novel nuances across products.The goal of any drug product development is to manufacture a product to a predefined quality and to realize a process that is robust and reproducible. The objective is to deliver a product that meets quality, safety, and efficacy requirements.For any drug product development program, CMC is directly on the critical path. Although it may be possible to compact some time and cost aspects through strategic consideration, the wake-up call is that there are no shortcuts for the attributes of quality and safety. The CMC is the clinical product, so it must be pitch perfect. Advanced therapies have more complex parts, with which developers must deal in terms of their characterization, manufacture, controls, and applied specifications. All these factors need adequate development time to apply the appropriate measures, or else the entire development program runs the risk of stumbling and falling at some point thereafter.Some exemplary common CMC consideration points (not exhaustive) where cell therapy (CT) and gene therapy (GT) programs can be tripped are:Manufacturing process

It is important to note that these statutory timelines may not accurately apply to all GMO-based products during the current COVID-19 health emergency. In June 2020, the European Commission issued a proposal to relax requirements specifically for clinical trials exploring GMO-containing COVID-19 treatments and vaccines. The proposal suggests allowing temporary derogation from requirements of Directives 2001/18/EC and 2009/41/EC for products to treat or prevent COVID-19 for the duration of the pandemic.8 This temporary relaxation of requirements does not apply to treatments for other diseases. Readers are advised to enquire with individual national agencies about any changes in process and timelines during the COVID-19 pandemic because these may be updated frequently.LogisticsWhile additional approval requirements on the critical path might directly affect the clinical trial start-up time, various other logistical considerations at site level can also influence the timeline and/or overall feasibility of the trial. The logistical challenges will depend on the type of product. For example, products based on living cells, such as cell therapies and cell-based gene therapies, have an inherently short shelf life at ambient temperatures so careful consideration should be given to transportation logistics from the site of the source biopsy to the manufacturing facility, and to the return to the clinical site for autologous/allogeneic patient administration. Handling of the starting material (such as the patients own cells for an autologous cell-based therapy) and the final drug product may require use of specialized equipment, such as laminar flow hoods, cryogenic storage, special centrifuges. Staff must be appropriately trained to use the equipment and handle the products. Moreover, certain advanced therapy products require the co-use of specific medical devices.The preceding considerations are a small fraction of the overall logistical requirements for conducting a global advanced therapy clinical study. Contract research organizations, or CROs, have a key role in providing training for nurses, physicians, pharmacists, and other site staff, as well as providing clinical logistics coordination to oversee patient and sample transportation and tracking in close collaboration with sites and sponsors.

Patient counseling and eligibilityGenetic counseling as a prerequisite to genetic testing to evaluate patient eligibility for a clinical trial is an additional steppingstone in numerous countries. Some countries may require the general availability of counseling, whereas others mandate genetic counseling before genetic testing can be done. Also, specially trained personnel might be necessary to conduct the genetic testing. The specific national requirements should be factored in during clinical trial planning to ensure availability of qualified personnel as required and possibly included in the informed consent forms.Regulatory authority guidanceAdvanced therapy product development must follow all good practice requirements for small-molecule and biologic products. However, owing to the complexity of the products and added risks to clinical trial subjects, there are further specific requirements for advanced therapies. In addition, clinical trial design may need to encompass specifically tailored trial designs including single-arm studies and/or study designs using a synthetic control arm. In many cases, it is not feasible and/or ethical to conduct standard double-blind studies for advanced therapies because of the invasive methods used to extract human source material or administer the advanced therapy product, and ease of distinction between placebo and investigational product.Furthermore, all advanced therapies require extended, long-term follow-up periods and/or the establishment of registries. The use of tailored trial designs is critical to ensure a time and cost-effective development program leading to patient and payer acceptance.Global regulators recognize the value of advanced therapies, particularly given their potentially curative effect, and they have provided ample guidance for all stages of product development. Recent guidance on clinical study design also addresses the need for deviation from traditional study designs to those involving more real-world data. Available key guidance documents in the European Union and the US will be the subject of an upcoming publication.Early interactions with regulatory and health authorities is encouraged to obtain supportive direction and acknowledgment of the approaches to be taken in the development program. Key regulators have pointed out it is pertinent to understand the product and its aims as early as possible to provide proactive advice with this further alluding to the avoidance of common trip hazards. This also further opens the door to priority advanced therapy support vehicles, such as EMA and FDA early scientific advice (e.g. INTERACT, pre-investigational new drug meetings), participation in the regenerative medicine advanced therapy and the EMAs priority medicines schemes, where possible, and other more widely available mechanisms supporting efficient product development.ConclusionAdvanced therapies are a dynamic and fast-growing sector of the pharmaceutical industry. Due to their additional complexity over traditional biologics, they require added ingenuity in line with the particular nature of the cell or gene therapy product type, demanding a carefully considered technical and regulatory development approach to anticipate and mitigate potential risks upfront.Regulatory agencies have implemented additional requirements for overall product development, the conduct of clinical trials and/or data needed for product approval. It is therefore imperative to conduct an in-depth regulatory intelligence collection with national requirements for countries intended to be included in the clinical trial. The investigation of associated timelines, particularly for GMO-based products, will also ensure a country selection that supports an achievable timeline for study start-up in a global environment.Developers of advanced therapies also need to include strategies beyond the clinical development to ensure patient access with a sound understanding of not only regulatory expectations but also the health technology assessment/payer evidence requirements to ascertain approval and reimbursement. The important take-home messages are to begin with the end in mind and to develop sound technical and regulatory strategies, to better anticipate and avoid many of the trip hazards that could prove costly, both in time and money, all of which could critically affect the overall clinical study program.AbbreviationsCMC, chemistry, manufacturing, and controls; CT, cell therapy; EMA; European Medicines Agency; EU, European Union; FDA, [US]Food and Drug Administration; GT, gene therapy; GMO, genetically modified organisms; NIH, National Institutes of Health; RAC, Recombinant DNA Advisory CommitteeReferencesAll websites were accessed on 31 July 2020.

Continue reading here:
Advanced therapies: 'Trip hazards' on the development pathway - Regulatory Focus

The Report Titled On DTC Genetic Testing Market includes Market Size (Production, Consumption, Value and Volume), Upstream Situation, Market Segmentation, DTC Genetic Testing Market Segmentation, Price & Cost And Industry Environment. In addition, the report outlines the factors driving industry growth and the description of market channels. The prime objective of this DTC Genetic Testing market report is to help the user understand the market in terms of its Definition, Segmentation, Market Potential, Influential Trends, and the Challenges that the Market Is Facing.

The DTC Genetic Testing Market profile also contains descriptions of the leading topmost manufactures/players like (23andMe, Ancestry, Color, EasyDNA, Family Tree DNAGene by Gene, Full Genomes, Genesis HealthCare, Helix, Identigene, Karmagenes, Living DNA, MapMyGenome, MyHeritage, Pathway Genomics)which including Capacity, Production, Price, Revenue, Cost, Gross, Gross Margin, Growth Rate, Import, Export, Market Share and Technological Developments.

Get Free Sample PDF (including full TOC, Tables and Figures)of DTC Genetic Testing[emailprotected]https://www.researchmoz.us/enquiry.php?type=S&repid=2423654

Scope of DTC Genetic Testing Market:Direct-to-consumer genetic testing is different: these genetic tests are marketed directly to customers via television, print advertisements, or the Internet, and the tests can be bought online or in stores. Customers send the company a DNA sample and receive their results directly from a secure website or in a written report. Direct-to-consumer genetic testing provides people access to their genetic information without necessarily involving a healthcare provider or health insurance company in the process.

On the basis of product, this report displays the sales volume, revenue (Million USD), product price, market share and growth rate of each type, primarily split into-

Targeted Analysis Single Nucleotide Polymorphism (SNP) Chips Whole Genome Sequencing (WGS)

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of DTC Genetic Testing for each application, including-

Carrier Testing Predictive Testing Ancestry and Relationship Testing Nutrigenomics Testing Others

Do You Have Any Query Or Specific Requirement? Ask to Our Industry[emailprotected]https://www.researchmoz.us/enquiry.php?type=E&repid=2423654

Geographically, the report includes the research on production, consumption, revenue, DTC Genetic Testing market share and growth rate, and forecast (2020-2026) of the following regions:

Key Developments In The DTC Genetic Testing Market:

To describe DTC Genetic Testing Introduction, product type and application, market overview, DTC Genetic Testingbmarket analysis by countries, market opportunities, market risk, market driving force;

To analyze the manufacturers of DTC Genetic Testing market, with profile, main business, news, sales, price, revenue and market share in 2016 and 2020;

To display the competitive situation among the top manufacturers in North America, with sales, revenue and DTC Genetic Testing market share in 2016 and 2020;

To show the market by type and application, with sales, price, revenue,DTC Genetic Testing market share and growth rate by type and application, from 2013 to 2020;

To analyze the key countries by manufacturers, Type and Application, covering United States , Canada and Mexico, with sales, revenue and DTC Genetic Testing market share by manufacturers, types and applications;

DTC Genetic Testing market forecast, by countries, type and application, with sales, price, revenue and growth rate forecast, from 2020 to 2026;

To analyze the DTC Genetic Testing market manufacturing cost, key raw materials and manufacturing process etc.

To analyze the industrial chain, sourcing strategy and downstream end users (buyers);

To describe DTC Genetic Testing market sales channel, distributors, traders, dealers etc.

To describe DTC Genetic Testing market Research Findings and Conclusion, Appendix, methodology and data source.

Contact:

ResearchMozMr. Rohit Bhisey,Tel: +1-518-621-2074USA-Canada Toll Free: 866-997-4948Email:[emailprotected]

Browse More Reports Visit @https://www.mytradeinsight.blogspot.com/

See the original post here:
DTC Genetic Testing Market 2020-2026: Analysed By Business Growth, Development Factors, Applications, And Future Prospects - Market Research...

The MSK expert explained that pre- and post-test educatin on genetic testing could help patients and providers alike to better understand the results.

Pre- and post-test education on genetic testing may help patients disseminate information more easily to their health care providers, according to Kelly Morgan, MS, CGC.

In a recent study, presented at the 2020 ASCO Virtual Scientific Program, the BRCA Founder OutReach (BFOR) offered pre-testing online education with posttest engagement of primary care providers, which appeared to be effective in educating both patients and providers alike.

So, in terms of the participant experience, we found satisfaction to be high both after this pre-test education and also after genetic testing. Knowledge was high after the pre-test education, which was very important from our perspective to make sure our participants were able to adequately receive the information they need to make a decision like this, said Morgan, a genetic counselor at Memorial Sloan Kettering Cancer Center.

In an interview with CancerNetwork, Morgan explained how these results can affect health care providers knowledge of genetic testing moving forward.

Transcription:

From our perspective, we really see this model as a way to more effectively disseminate information. So whether that be to patients but also importantly to their doctors. So you're absolutely right in terms of having a multidisciplinary team and the more that we can engage not only a patient, but their community and their providers to build the biggest sort of network of resources we can, I think that's important. And these digital tools I think, can create a centerpiece for patients and their physicians to come together and both learn

Read the rest here:
Kelly Morgan, MS, CGC, on Genetic Testing Education Aiding in Disseminating Information - Cancer Network

Genetic testing may be a helpful tool in diagnosing autism and intellectual disability, but published data does not adequately support its use as a standard predictor of antidepressant response, James B. Potash, MD, MPH, said during a session at the virtual 2020 Psych Congress Elevateconference on the role of genetic testing in psychiatry.

There is ample reason to think that genetic variation ought to predict antidepressant response but research has shown mixed results, said Dr. Potash, who is the Henry Phipps Professor, Director and Psychiatrist-in-Chief, at Johns Hopkins Medicine, Baltimore, Maryland, and has been working in the field of genetics of mood disorders for more than 20 years.

Dr. Potash is a member of the American Psychiatric Association Council on Research, which had a task force analyze the issue in recent years. In a systematic review of pharmacogenetic tests of antidepressants, the task force found that the quality of the data provided by the tests on pharmacodynamicshow a drug affects the brainwas low, he said. However, the study, published in The American Journal of Psychiatry, found the tests provided higher-quality data on regarding particular genes related to how a drug is metabolized in the liver.

Their conclusion was at present there are insufficient data to support the widespread use of combinatorial pharmacogenetic testing in clinical practice, although there are clinical situations in which the technology may be informative, particularly in predicting side effects, Dr. Potash explained.

Similarly, an International Society of Psychiatric Genetics committee on genetic testing last year reached the conclusion that evidence to support widespread use of pharmacogenetic tests is inconclusive. But the statement also says when pharmacogenetic testing results are already available, providers are encouraged to integrate this information into their medication selection and dosing decisions, he said.

As for the future direction of genetic testing in psychiatry, Dr. Potash said there is ongoing research into its use in bipolar disorder.

A study involving 2500 people with bipolar disorder, published in Lancet by the International Consortium on Lithium Genetics, found some genetic variations were statistically significantly associated with response to lithium treatment. People with the highest Polygenic Risk Score (PRS) for schizophrenia had the lowest response to lithium treatment, and people with the lowest schizophrenia PRS had the highest response to lithium treatment. In addition, a paper recently published in Molecular Psychiatry found that people with bipolar disorder who had the lowest PRS for depression were 75% more likely to respond favorably to lithium, compared with those with the highest depression PRS scores.

Dr. Potash also spoke about the importance of a more traditional genetic research tool: collecting a detailed family history from a patient.

It has been known for a long time but its not always implemented, he said, noting that familial recurrence risk has been analyzed for more than 100 years.

For example, he explained, if one parent has schizophrenia and no siblings or second-degree relatives do, a child has a 6% risk of developing schizophrenia. But if one parent, two siblings, and a second-degree have the disorder, the relative the risk of a child inheriting it is 36%.

That kind of information is important, he said. Very important. Its valuable.

Terri Airov

References

Amare AT, Schubert KO, Hou L.,et al.Association of polygenic score for major depression with response to lithium in patients with bipolar disorder.Molecular Psychiatry. 2020 March 16;[Epub ahead of print].

Genetic Testing Statement. International Society of Psychiatric Genetics. Accessed July 15, 2020.

Hou L, Heilbronner U, Degenhardt F, et al. Genetic variants associated with response to lithium treatment in bipolar disorder: a genome-wide association study. Lancet. 2016;387(10023):1085-1093.

The role of genetic testing in psychiatry. Presented at Psych Congress Elevate: Virtual; July 26, 2020.

Zeier Z, Carpenter LL, Kalin NH, et al. Clinical implementation of pharmacogenetic decision support tools for antidepressant drug prescribing. The American Journal of Psychiatry. 2018;175:873886.

View original post here:
The Limitations and Promise of Genetic Testing in Psychiatry - Psych Congress Network

This article was originally published here

J Gen Intern Med. 2020 Jul 27. doi: 10.1007/s11606-020-06064-x. Online ahead of print.

ABSTRACT

BACKGROUND: Prior studies suggest that referral to genetic counseling and completion of genetic testing vary by race/ethnicity; however, the data are limited.

OBJECTIVE: We sought to evaluate patterns of genetic testing and clinical outcomes across race/ethnicity at a hereditary breast and ovarian cancer center.

DESIGN: The medical records for all patients undergoing genetic assessment at a hereditary breast and ovarian cancer center were reviewed and stratified by self-reported race/ethnicity (non-Hispanic White, Hispanic, non-Hispanic Black, and Asian).

PARTICIPANTS: A total of 1666 patients met inclusion criteria (non-Hispanic Whites, 1367; Hispanics, 85, non-Hispanic Blacks, 101; Asians, 113).

MAIN MEASURES: Demographics, patient characteristics, and referral patterns for patients who underwent genetic testing were analyzed using Kruskal-Wallis tests, chi-square test, or Fishers exact tests, stratifying by self-reported race/ethnicity. Pathogenic mutations and variants of unknown significance (VUS) were reviewed. Outcomes of patients with genetic mutations and personal history of breast and/or gynecologic malignancies were compared.

KEY RESULTS: Non-Hispanic Whites were more likely to be referred due to family cancer history compared to all other ethnicities while Non-Hispanic Blacks, Hispanics, and Asians were more likely to be referred due to personal history of cancer (p < 0.001). Non-Hispanic Blacks and Hispanics were more likely to have advanced-stage cancer at the time of genetic testing (p < 0.02). Rates of mutations did not differ by race/ethnicity when Ashkenazi Jewish patients were excluded (p = 0.08). Among patients found to have a BRCA1/2 mutation, Non-Hispanic Whites were more likely to undergo cancer screening and risk-reducing surgery compared with all other ethnicities (p = 0.04).

CONCLUSIONS: Minority patients were more likely to utilize genetic services following a cancer diagnosis and less likely due to family cancer history, suggesting a missed opportunity for mutation detection and cancer prevention in this population. Efforts to eradicate racial/ethnic disparities in early access to genetic testing and guided cancer prevention strategies are essential.

PMID:32720237 | DOI:10.1007/s11606-020-06064-x

See the rest here:
Racial and Ethnic Disparities in Genetic Testing at a Hereditary Breast and Ovarian Cancer Center - DocWire News

The Global At Home Genetic Testing Market Research Report provides customers with a complete analytical study that provides all the details of key players such as company profile, product portfolio, capacity, price, cost, and revenue during the forecast period from 2020 to 2027. The report provides a full assessment. At Home Genetic Testing market with future trends, current growth factors, meticulous opinions, facts, historical data and statistically supported and industry-validated market data.

This At Home Genetic Testing market research provides a clear explanation of how this market will impress growth during the mentioned period. This study report scanned specific data for specific characteristics such as Type, Size, Application and End User. There are basic segments included in the segmentation analysis that are the result of SWOT analysis and PESTEL analysis.

To Learn More About This Report, Request a Sample Copy:https://www.worldwidemarketreports.com/sample/339093* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

23andMe, MyHeritage, LabCorp, Myriad Genetics, Ancestry.com, Quest Diagnostics, Gene By Gene, DNA Diagnostics Center, Invitae, IntelliGenetics, Ambry Genetics, Living DNA, EasyDNA, Pathway Genomics, Centrillion Technology, Xcode, Color Genomics, Anglia DNA Services, African Ancestry, Canadian DNA Services, DNA Family Check, Alpha Biolaboratories, Test Me DNA, 23 Mofang, Genetic Health, DNA Services of America, Shuwen Health Sciences, Mapmygenome, Full Genomes are some of the major organizations dominating the global market.(*Note: Other Players Can be Added per Request)

Key players in the At Home Genetic Testing market were identified through a second survey, and their market share was determined through a primary and second survey. All measurement sharing, splitting, and analysis were solved using a secondary source and a validated primary source. The At Home Genetic Testing market report starts with a basic overview of the Industry Life Cycle, Definitions, Classifications, Applications, and Industry Chain Structure, and when used together, how key players can meet market coverage, offered characteristics, and customer needs It helps to understand.

The report also makes some important suggestions for new At Home Genetic Testing market projects before evaluating their feasibility. Overall, this report covers At Home Genetic Testing market Sales, Price, Sales, Gross Profit, Historical Growth,and Future Prospects. It provides facts related to the widespread merger, acquisition, partnership, and joint venture activities on the market.

This report includes market size estimates of value (million US $) and trading volume (K MT). The top-down and bottom-up approaches are used to estimate and validate the market size of the At Home Genetic Testing market, estimating the size of various other subordinate markets in the overall market. All ratio sharing, splitting, and analysis were determined using the secondary source and the identified primary source.

What At Home Genetic Testing Market report offers:

Remarkable Attributes of At Home Genetic Testing Market Report:

Share Your Precise Requirements: https://www.worldwidemarketreports.com/quiry/339093

Special Requirements?We value your investment and offer customization as per your requirements.

About WMR

Worldwide Market Reports is your one-stop repository of detailed and in-depth market research reports compiled by an extensive list of publishers from across the globe. We offer reports across virtually all domains and an exhaustive list of sub-domains under the sun. The in-depth market analysis by some of the most vastly experienced analysts provide our diverse range of clients from across all industries with vital decision making insights to plan and align their market strategies in line with current market trends.

Contact Us:

Mr. ShahWorldwide Market ReportsSeattle, WA 98154,U.S.Email: [emailprotected]

See more here:
At Home Genetic Testing Market: an Increase in Revenue That Will Change the Game After COVID 19: 23andMe, MyHeritage, LabCorp - Market Research Posts

By Dr. Lynn Webster, PNN Columnist

Millions of Americans order DNA test kits to determine their ancestries. Knowing where you come from can be entertaining. However, DNA testing can also help identify your risk of developing some diseases, including chronic pain.

Prenatal testing for genetic disorders is common. But genetic testing is also increasingly used to determine the risk of developing certain diseases or potential responses to specific drugs.

Currently, little is known about how to use genes to make an individual more or less sensitive to pain, or to learn the likelihood that someone will respond in a particular way to an analgesic based on their genetics. The good news is that we are on the cusp of gaining more information about the genes that control pain and pain treatments, and that knowledge should allow us to develop targeted pain therapies.

Most physicians still believe that everyone experiences pain in the same way. Research recently published in Current Biology discovered a genethe so-called "Neanderthal gene"that is associated with increased sensitivity to pain. Recognizing that a mutation of a specific gene can influence pain perception may be illuminating for many members of the medical profession.

Pain specialists have known for a long time that given the same stimulus, some people feel more pain than others. The truth is, there are several genes besides the Neanderthal gene that determine how an individual experiences pain. Some genes increase our sensitivity to pain, while other genes decrease it. Some genes influence how pain is processed, while other genes determine an individual's response to an analgesic.

The ability for an analgesic to provide pain relief in an individual is partially determined by the genetics of the receptor to which the pain medication binds. These genes are different from pain-sensitivity genes. For example, oxycodone may be very effective in relieving pain for one individual, but only partially effective for another.

Optimal pain relief requires recognition that each individual responds uniquely to a given analgesic. Doctors are beginning to provide gene therapy for cancer patients. Advancements in research may someday allow us to do the same for patients with pain.

The array of pain responses to the same stimulus is a major reason why one-size-fits-all dosing of pain medications is flawed. A given dose may leave some patients undertreated and others over-treated. Unfortunately, regulators who set arbitrary dose limits fail to understand or consider this biologic variability.

Differing clinical responses to pain stimuli and medications underscore the need to individualize therapy. Knowing more about the biology of pain can help us to understand each individuals response to painful stimuli and the variable response to any therapy.

How we experience pain is a result of both environmental and genetic features. The genetic factors are what we inherit. Environmental factors which we develop rather than inherit include cultural attitudes, emotions, and individual responses to stress. Our personality and lifes experiences are included in the environmental factors that contribute to our experience of pain. Therefore, pain is a result of genetic and environmental interactions. Both can make an individual more or less sensitive to stimuli or analgesia. It is a complex and dynamic process.

The so-called Neanderthal gene is not a new discovery but was newly recognized in Neanderthals. The discovery is interesting, because it implies the gene has an evolutionary purpose. The gene is known as SCN9. There are several pain syndromes associated with the genetic mutations of the SCN9 gene, including some types of back pain and sciatica. Mutations of this gene can result in the total absence of pain or a heightened pain expression. The type of mutation determines the phenotype (or personal characteristics) of our response to a painful stimulus.

It is unclear how Neanderthals benefited biologically from increased pain sensitivity. As we know, acute pain elicits an alarm and is considered protective. It teaches us to avoid dangers that can threaten our life, and prevents us from walking on a broken leg until it heals sufficiently to bear our weight.

Evolution may not have been concerned about the effects of chronic pain. The Neanderthals' limited life expectancy, and the fact that their survival depended on strong physical conditioning, may have made chronic pain a non-issue. Chronic pain may have made survival difficult, or even impossible, for the Neanderthals.

The recent discovery that Neanderthals had the SCN9 gene should not be surprising, given the fact that modern humans shared a common ancestor with Neanderthals. The Neanderthal gene study is of particular interest to me, because I am working with several companies that are exploring potential drugs to affect the function of the SCN9 gene. The companies have different approaches, but they all are trying to find a way to dial down an individual's sensitivity to painful stimuli.

Since the SCN9 gene can be responsible for the total absence of all pain, as well as several extreme forms of pain, it may be reasonable to target the SCN9 gene to modulate pain.

My hope is that manipulation of the SCN9 gene will reduce pain sensitivity, making it easier to control pain by adjusting the dose and type of drug we prescribe.

It is possible one or more drugs that target the SCN9 gene will be available within the next 4-6 years. If that occurs, it could be game changer for people in pain. We can then thank our Neanderthal ancestors for the evolutionary gift.

Lynn R. Webster, MD, is a vice president of scientific affairs for PRA Health Sciences and consults with the pharmaceutical industry. He is author of the award-winning book, The Painful Truth, and co-producer of the documentary, It Hurts Until You Die. You can find Lynn on Twitter: @LynnRWebsterMD

Continue reading here:
Genetic Studies Could Pave the Way to New Pain Treatments - Pain News Network

The Europe Genetic Testing Market report 2020 covers all the significant developments which are recently being adopted across the global market. The prime objective of the Europe Genetic Testing market report is to provides an in-depth analysis of all market dynamics including drivers and restraints, and trends, and opportunities. The Europe Genetic Testing market report covers both the demand and supply aspects of the market. The report also highlighted the future trends in the Europe Genetic Testing market that will impact the demand during the forecast period.

Scope of the Report:

As per the scope of this report, genetic testing is a test performed to identify the presence of a particular gene/s with a particular sequence of the genome. The gene/s can be identified either directly through sequencing or indirectly through various methods.

Get a Sample Copy of the Report https://www.industryresearch.co/enquiry/request-sample/13999555

Market Overview:

Some of the Top Key Players of Europe Genetic Testing Market Report Are:

Report Highlights:

For More Information or Query or Customization Before Buying, Visit at https://www.industryresearch.co/enquiry/pre-order-enquiry/13999555

Key Market Trends:

Diagnostic testing is the segment under type of testing that is expected to grow fastest during the forecast period

Predictive and presymptomatic testing dominated the European genetic testing market system, as it is utilized for the detection of gene mutations related to disorders that appear after birth, frequently in later stages of life. Such tests can be of assistance to individuals having a family member with a genetic disorder, though they are free of any features of the disorder while testing.

Diagnostics testing is expected to register a CAGR of 14.29%, as it is used to diagnose or rule out a specific genetic condition. In most cases, genetic testing is used to confirm a diagnosis when a particular condition is suspected based on physical mutations and symptoms. Furthermore, companies, such as Centogene and NIMGenetics, offer a wide range of genetic diagnostic services in Europe, which is further accelerating the growth of the market.

The Report Covers:

Purchase this Report (Price 3850 USD for single user license) https://www.industryresearch.co/purchase/13999555

Detailed TOC of Europe Genetic Testing Market Report 2020-2024:

1 INTRODUCTION1.1 Study Deliverables1.2 Study Assumptions1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS4.1 Market Overview4.2 Market Drivers4.2.1 Increasing Emphasis on Early Disease Detection and Prevention4.2.2 Increasing Demand for Personalized Medicine4.2.3 Increasing Application of Genetic Testing in Oncology4.3 Market Restraints4.3.1 High Costs of Genetic Testing4.3.2 Social and Ethical Implications of Genetic Testing4.4 Porters Five Forces Analysis4.4.1 Threat of New Entrants4.4.2 Bargaining Power of Buyers/Consumers4.4.3 Bargaining Power of Suppliers4.4.4 Threat of Substitute Products4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION5.1 Type5.1.1 Carrier Testing5.1.2 Diagnostic Testing5.1.3 Newborn Screening5.1.4 Predictive and Presymptomatic Testing5.1.5 Prenatal Testing5.1.6 Nutrigenomic Testing5.2 Disease5.2.1 Alzheimers Disease5.2.2 Cancer5.2.3 Cystic Fibrosis5.2.4 Sickle Cell Anemia5.2.5 Duchenne Muscular Dystrophy5.2.6 Thalassemia5.2.7 Huntingtons Disease5.2.8 Special Disease5.2.9 Other Diseases5.3 Technology5.3.1 Cytogenetic Testing5.3.2 Biochemical Testing5.3.3 Molecular Testing5.4 Geography5.4.1 Europe5.4.1.1 Germany5.4.1.2 United Kingdom5.4.1.3 France5.4.1.4 Italy5.4.1.5 Spain5.4.1.6 Rest of Europe

6 COMPETITIVE LANDSCAPE6.1 Company Profiles6.1.1 Illumina Inc.6.1.2 Abbott Laboratories6.1.3 23andMe Inc.6.1.4 F. Hoffmann-La Roche Ltd6.1.5 Qiagen6.1.6 Blueprint Genetics Oy6.1.7 Eurofins Scientific6.1.8 Centogene AG6.1.9 Thermo Fisher Scientific6.1.10 Elitech Group

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Contact Us:

Name: Ajay More

Phone: US +14242530807/ UK +44 20 3239 8187

Email: [emailprotected]

Our Other Reports:

Marble Flooring Market Size and Growth Insights by Global Key Players 2020 Evolving Technologies with Market Dynamics, Opportunities, Industry Trends Forecast to 2026

Kefir Market Growth Analysis 2020 Global Manufacturing Share, Industry Size, Expected Revenue with CAGR, Emerging Trends, and Industry Updates Forecast by 2023

Mobile and Wireless Backhaul Equipment Market Size 2020 Global Industry Share, Share, Demand, Key Findings, Regional Analysis, Key Players Profiles, Future Prospects and Forecasts to 2023

Lithium Hydroxide Market Size and Share Forecast to 2024 | Global Industry Analysis by Dynamics Trends, Company Overview, Growth Factors

Mobile Camera Chip Market 2020 Industry Outlook by Business Growth, Industry Price Trend, Size Estimation, Report Latest Research, Business Analysis and Forecast Research till 2025

AC Electrical Film Capacitor Market by Major Drivers 2020 Global Industry Insights by Global Players, Regional Segmentation, Growth, Applications, Value and Forecasts till 2026

See the original post here:
Europe Genetic Testing Market 2020 | Research Objectives and Methodology, Growth Analysis, Top Manufacturers Sales, and Cost Structures Forecast 2024...

A 23andMe Inc. DNA genetic testing kit.

Photographer: Cayce Clifford/Bloomberg

Photographer: Cayce Clifford/Bloomberg

U.K. drugmaker GlaxoSmithKline Plc and genetic-testing giant 23andMe Inc. have begun their first joint human clinical trial as part of a collaboration to leverage the Silicon Valley firms DNA database to develop drugs.

The companies said that they enrolled their first patientthis month in early-stage trials for a drug that targets human tumors. The drug is an antibody that works to block CD96, a proteinthat plays a role in modulating the bodys immune responses. The theory is that blocking it will help control the activity of another molecule in the body called CD155 that is often over-expressed in malignant human tumors.

GSK took a $300 million stake in 23andMe in 2018in a deal to share its data and collaborate on drug development.The idea was to comb DNA data and health information volunteered by 23andMes more than 12 million customersto hunt for clues as to the role genetics playin different diseases and then translate those insights into potential new drugs.

This is a new way of thinking about drug development, Hal Barron, GSKs chief scientific officer and president of research and development, said in an interview. And the concept is coming to bear.

There is much enthusiasm in the pharmaceutical world for the pathway that these companies are targeting. Prior to teaming up, both had their own programs to explore CD96. 23ndMe tapped into its database to validate GSKs approach, using an algorithm that compared potential drug targets to a data set that included genetic information along with other health data shared by customers in order to identify genetic patterns.

Its an important target, Barron said. Hopefully well find out in the clinic that it helps patients fight cancer, and maybe even aids the immune system in eradicating it. That would be the ideal situation.

The two companies have nearly 30 programs underway exploring potential drug targetsin oncology, immunology, neurology, cardiovascular and metabolic disease. The vast majority are still in the early stages of validating those molecular pathways; for a few, drug discovery efforts are already underway.

What has surprised me the most is how well this approach has worked, how productive its been, said 23andMe Chief Executive Officer Anne Wojcicki.

Identifying a molecular pathway that plays a role in a disease is only part of the hurdle in developing a drug. Even once its clear that a target is involved in a disease, altering it could have other negative health impacts or simply be difficult to design a drug due to the intricacies of human biology.

While its unlikely all thosewill make it to clinical trials, Barron said thatusing genetics to find potential drug targets will hopefully lead to a higher probability thoseultimately result in effective medicines.

23andMe launched its therapeutics program five years ago, and its become an increasingly large focus of the company. In January, it licensed an antibody it had developed to treat inflammatory diseases to Spanish drugmaker Almirall SA. The company is individually pursuing other drug candidates, some of which it may put through clinical trials itself rather than licensing out to other companies.

Before it's here, it's on the Bloomberg Terminal.

Here is the original post:
23andMe and GSK Head to Clinical Trials With Cancer Drug - Bloomberg

Exercise can help prevent excess fatigue for survivors of cancer and other issues are explored in this summer issue of CURE.

Unlike tiredness from a hard day at work or a vigorous workout, cancer fatigue can be unrelated to a persons activities yet all encompassing. The phenomenon can be difficult for those who have never had cancer to understand.

(Friends) really do not get it when I need to go home and climb into bed immediately or am unable to take one more step or have to cancel an engagement, Jane Biehl, a CURE Voices contributor, wrote in a May 15 blog. Before cancer, willpower carried me through fatigue, but no more. That weight all over my body frankly kicks my butt.

In this issue of CURE, we take an in-depth look at cancer fatigue, its causes and a variety of treatment options. Perhaps counterintuitively, experts point out that the most effective therapy for this condition is exercise, a remedy that could seem daunting. Research consistently supports this idea, and our article describes the kinds of programs that work best.

In another feature, we tackle the topic of radiopharmaceuticals, radioactive drugs with an expanding role in both treatment and diagnosis. The expectation is that more of these drugs will be discovered over the next decade, and additional uses will be found for those already on the market. Our article discusses the fascinating area called theranostics or using the same radiopharmaceutical to both diagnose and treat a specific cancer.

Elsewhere in the treatment arena, we bring highlights from Junes annual meeting of the American Society of Clinical Oncology, including findings in colorectal, bladder, ovarian and non-small cell lung cancers. This issue also covers investigational treatments for chronic lymphocytic leukemia and kidney cancer.

At the other end of the spectrum, we look at the time before cancer develops and how people can protect themselves. With the help of a Northwestern University expert in epidemiology and cancer prevention, we examine recommended strategies for avoiding the disease. A separate piece explores whether those who had genetic testing years ago should repeat the process using todays more sophisticated tests to get a more comprehensive picture of whether they have any inherited cancer-causing genes.

Finally, we come full circle with another article on easing a side effect, in this case hair loss during chemotherapy. In an interview, an oncology expert answers our questions about the safety, effectiveness and availability of cold caps.

We hope that these articles, which span the cancer journey from prevention to survivorship, leave you better informed about strategies that can help you lead a healthier and more comfortable life. As always, thank you for reading.

Original post:
Exercise Can Help Ease Excessive Fatigue in Survivors of Cancer - Curetoday.com

In its recently published report, Report Ocean has provided unique insights about the Direct-To-Consumer (DTC) Genetic Testing Market. The main objectives of this research report is to categorize the various dynamics of the market and to offer latest updates such as mergers and acquisitions, various technological developments, new entrants in the market, which make an impact on different segments of the Direct-To-Consumer (DTC) Genetic Testing Market.

This research report offers in-depth study about Market Size and Share, Product and Services, Company Profile, Regional Forecast, Consumer Preference, Market Competition, and Industry Chain Structure.

This research report represents the statistical data in the form of TABLES, CHARTS, and infographics to assess the market, its growth and development, and market trends of the Direct-To-Consumer (DTC) Genetic Testing Market during the forecasted period.

COVID 19 Impact on Direct-To-Consumer (DTC) Genetic Testing Market

The Coronavirus Pandemic (COVID-19) has affected every aspect of life worldwide. Under COVID-19 Outbreak, how the Direct-To-Consumer (DTC) Genetic Testing Market will develop is also analyzed in detail in Chapter 1.7 of the report.

In Chapter 2.4, we analyzed industry trends in the context of COVID-19.

In Chapter 3.5, we analyzed the impact of COVID-19 on the product industry chain based on the upstream and downstream markets.

In Chapters 6 to 10 of the report, we analyze the impact of COVID-19 on various regions and major countries.

In chapter 13.5, the impact of COVID-19 on the future development of the industry is pointed out.

Request Free Sample Report athttps://www.reportocean.com/industry-verticals/sample-request?report_id=mai28982

Competitive Landscape:

Key players in the global Direct-To-Consumer (DTC) Genetic Testing market covered in Chapter 4:Myriad GeneticsMD RevolutionDeCODEme23andMeGenetrainerGeneByGeneDNA DTCGenecodebook OyNavigenicsThis report also outlines the Major companies or players involved in the Direct-To-Consumer (DTC) Genetic Testing Market, along with product specifications, revenue generated, pricing strategies, contact information, information related to raw materials, equipment and demands. With the help of tables and figures, valuable insights on production, value, price, and gross margin of each player are offered.

Market Segmentation:

The segmentation study is considered as the key section to decide the target market with keen study of segments or smaller sections such as geographical regions, application and product type to optimize advertising technique and marketing strategies at regional as well as global level of the Direct-To-Consumer (DTC) Genetic Testing Market.

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2020-2026) of the following regions are covered in Chapter 5, 6, 7, 8, 9, 10, 13:

North America (Covered in Chapter 6 and 13)

United States

Canada

Mexico

Europe (Covered in Chapter 7 and 13)

Germany

UK

France

Italy

Spain

Russia

Others

Asia-Pacific (Covered in Chapter 8 and 13)

China

Japan

South Korea

Australia

India

Southeast Asia

Others

Middle East and Africa (Covered in Chapter 9 and 13)

Saudi Arabia

UAE

Egypt

Nigeria

South Africa

Others

South America (Covered in Chapter 10 and 13)

Brazil

Argentina

Columbia

Chile

Others

Some of the Major Highlights of TOC covers:

Report Overview

Study Scope

Key Market Segments

Regulatory Scenario by Region/Country

Market Investment Scenario Strategic

Global Market Growth Trends

Industry Trends

SWOT Analysis

Porters Five Forces Analysis

Potential Market and Growth Potential Analysis

Industry News and Policies by Regions

Industry News

Industry Policies

Industry Trends Under COVID-19

Value Chain of Direct-To-Consumer (DTC) Genetic Testing Market

Value Chain Status

Direct-To-Consumer (DTC) Genetic Testing Market Manufacturing Cost Structure Analysis

Production Process Analysis

Manufacturing Cost Structure of Direct-To-Consumer (DTC) Genetic Testing Market

Labor Cost of Direct-To-Consumer (DTC) Genetic Testing Market

Labor Cost of Direct-To-Consumer (DTC) Genetic Testing Market Under COVID-19

Sales and Marketing Model Analysis

Downstream Major Customer Analysis (by Region)

Value Chain Status Under COVID-19

Direct-To-Consumer (DTC) Genetic Testing Market Production, Revenue (Value), Price Trend by Type

Production and Market Share by Type

Revenue and Market Share by Type

Price by Type

Direct-To-Consumer (DTC) Genetic Testing Market Production, Consumption, Export, Import by Region

Production, Consumption, Export, Import by Region

Production, Consumption, Export, Import by Country

Production, Revenue, Price and Gross Margin

Industrial Chain, Sourcing Strategy and Downstream Buyers

Direct-To-Consumer (DTC) Genetic Testing Market Industrial Chain Analysis

Raw Materials Sources of Direct-To-Consumer (DTC) Genetic Testing Market major Players in 2019

Downstream Buyers

Direct-To-Consumer (DTC) Genetic Testing Market Forecast

Direct-To-Consumer (DTC) Genetic Testing Market Sales, Revenue and Growth Rate

Direct-To-Consumer (DTC) Genetic Testing Market Production, Consumption, Export and Import Forecast by Region

Direct-To-Consumer (DTC) Genetic Testing Market Production, Revenue and Price Forecast by Type

Direct-To-Consumer (DTC) Genetic Testing Market Consumption Forecast by Application

Direct-To-Consumer (DTC) Genetic Testing Market Forecast Under COVID-19

Years considered for this report:

Historical Years: 2015-2019

Base Year: 2019

Estimated Year: 2020

Forecast Period: 2020-2026

For more information and discount on this report, ask your query at:https://www.reportocean.com/industry-verticals/sample-request?report_id=mai28982

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe, and Asia.

Contact Us: +1 888 212 3539 (US) +91-9997112116 (Outside US)Contact Person: Matthew SEmail:[emailprotected]

The rest is here:
COVID-19 Impact on Direct-To-Consumer (DTC) Genetic Testing Market 2020- future development, manufacturers, trends, share, size and forecast details...

SALT LAKE CITY, July 29, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced today that the company has launched its proprietary AMPLIFY technology, which further increases the performance of its Prequelnoninvasive prenatal screening (NIPS) test. The proprietary AMPLIFY process increases the fetal fraction of a NIPS sample by preferentially sequencing the fetal cell-free DNA fragments that circulate in a mothers blood. AMPLIFY technology enables more accurate detection of fetal chromosome abnormalities. In the analytical validation involving samples from more than 1,000 pregnant women, fetal fraction is 2.3 times greater on average with AMPLIFY than with standard NIPS. This improvement reduces false positive and false negative resultsincluding for common aneuploidies, expanded aneuploidies, microdeletions and a babys sex. For instance, false negative performance in common aneuploidies improves 45x with AMPLIFY technology. Additionally, no samples powered by AMPLIFY technology had a fetal fraction below four percent. Other laboratories may fail samples with less than four percent fetal fraction.

Prequel already provided highly accurate results and this proprietary technology further increases the sensitivity of our test, said Nicole Lambert, president of Myriad International, Oncology and Womens Health. With AMPLIFY, Prequel maintains an industry-leading low rate of failed samplesdelivering results to 99.9 percent of patients. The important clinical benefits are that each woman who receives the test can expect highly accurate NIPS results, regardless of body mass index (BMI), race, or ethnicity.

Up to 50 percent of pregnant women present with high BMI to their healthcare provider. Studies have demonstrated that BMI is not evenly distributed across ethnicities, and up to 24 percent of women with high BMI will not receive a result on standard NIPS platforms due to low fetal fraction. Women who dont receive a result may do no further prenatal screening at all; they may go through subsequent rounds of NIPS, or they may undergo invasive procedures such as an amniocentesis or chorionic villus sampling, which can increase the risk of miscarriage and add unnecessary expense to the US healthcare system. Prequel with AMPLIFY technology overcomes the limitations of standard NIPS in order to provide equity of care to pregnant women.

About Prequel Prenatal ScreenThe Myriad Prequel Prenatal Screen is a non-invasive prenatal screen (NIPS) that uses cell-free DNA (cfDNA) to determine if a pregnancy is at an increased risk for chromosome abnormalities, such as Down syndrome. Compared to screening methods which use maternal age, ultrasound and serum screening, Prequel has been shown to be superior than by achieving a lower false-positive rate and false-negative rate than these other methods. Among other NIPS, Prequel has an industry leading test failure rate of 0.1 percent. The Prequel Prenatal Screen can be ordered with the Foresight Carrier Screen and offered to all women, including those with high body mass index, and ovum donor or a twin pregnancy.

About Myriad GeneticsMyriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. For more information on how Myriad is making a difference, please visit the Company's website: http://www.myriad.com.

Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice CDx, Vectra, Prequel, Foresight, GeneSight, riskScore and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.

Safe Harbor StatementThis press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to launch of the Companys proprietary AMPLIFY technology; and the Companys strategic directives under the caption "About Myriad Genetics." These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: uncertainties associated with COVID-19, including its possible effects on our operations and the demand for our products and services; our ability to efficiently and flexibly manage our business amid uncertainties related to COVID-19; the risk that sales and profit margins of our molecular diagnostic tests and pharmaceutical and clinical services may decline; risks related to our ability to transition from our existing product portfolio to our new tests, including unexpected costs and delays; risks related to decisions or changes in governmental or private insurers reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services and any future tests and services are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities and our healthcare clinic; risks related to public concern over genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to our projections about our business, results of operations and financial condition; risks related to the potential market opportunity for our products and services; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents or other intellectual property; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decisions in Mayo Collab. Servs. v. Prometheus Labs., Inc., 566 U.S. 66 (2012), Assn for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013), and Alice Corp. v. CLS Bank Intl, 573 U.S. 208 (2014); risks of new, changing and competitive technologies and regulations in the United States and internationally; the risk that we may be unable to comply with financial operating covenants under our credit or lending agreements; the risk that we will be unable to pay, when due, amounts due under our credit or lending agreements; and other factors discussed under the heading "Risk Factors" contained in Item 1A of our most recent Annual Report on Form 10-K for the fiscal year ended June 30, 2019, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law.

Visit link:
Myriad Launches Proprietary AMPLIFY Technology, Further Increasing the Performance of its Prequel NIPS Test - GlobeNewswire